desloratadine profile

desloratadine: major metabolite of loratadine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

desloratadine : Loratadine in which the ethoxycarbonyl group attached to the piperidine ring is replaced by hydrogen. The major metabolite of loratidine, desloratadine is an antihistamine which is used for the symptomatic relief of allergic conditions including rhinitis and chronic urticaria. It does not readily enter the central nervous system, so does not cause drowsiness. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	124087
CHEMBL ID	1172
CHEBI ID	291342
SCHEMBL ID	4425
MeSH ID	M0337021

Synonym
AC-1279
bdbm50073179
HMS3394H05
8-chloro-11-piperidin-4-ylidene-6,11-dihydro-5h-benzo[5,6]cyclohepta[1,2-b]pyridine
MLS000559042 ,
desloratadine
smr000149358
desalex
sch 34117
azomyr
5h-benzo(5,6)cyclohepta(1,2-b)pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)-
sch-34117
desloratadine [usan]
clarinex
neoclarityn
opulis
8-chloro-6,11-dihydro-11-(4-piperidinylidene)-5h-benzo(5,6)cyclohepta(1,2-b)pyridine
descarboethoxyloratadine
aerius
denosin
clarinex reditabs
allex
nsc-675447
nsc675447
descarboethoxyoratidine
desloratadine (jan/usp/inn)
100643-71-8
D03693
clarinex (tn)
MLS000759406
DB00967
NCGC00159325-02
NCGC00159325-03
cpd000149358
NCGC00159325-04
MLS001201801
HMS2093F19
HMS2052H05
HMS2090C06
D3787
AKOS000280921
L001025
CHEMBL1172 ,
desloratadine teva
desloratadine actavis
nsc-759824
dasselta
FT-0666048
8-chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5h-benzo[5,6]cyclohepta[1,2-b]pyridine
chebi:291342 ,
A19515
5h-benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)-
dtxsid1044196 ,
tox21_111574
dtxcid9024196
cas-100643-71-8
BBL010777
pharmakon1600-01505393
MLS001424247
nsc759824
STK586537
S4012
CCG-101162
desloratidine
mk-4117
desloratadine [usan:inn:ban]
nsc 759824
unii-fvf865388r
fvf865388r ,
FT-0602522
8-chloro-11-piperidin-4-ylidene-5,6-dihydrobenzo[1,2]cyclohepta[2,4-b]pyridine
gtpl7157
desloratadine actavis (authorized: rhinitis, urticaria)
desloratadine [ep monograph]
desloratadine ratiopharm
desloratadine [usp monograph]
desloratadine [vandf]
8-chloro-5,6-dihydro-11-(piperidin-4-ylidene)-11h-benzo[5,6]cyclohepta[1,2-b]pyridine)
clarinex-d component desloratadine
desloratadine [mi]
desloratadine ratiopharm (authorized: rhinitis, urticaria)
desloratadine teva (authorized: rhinitis, urticaria)
desloratadine [who-dd]
desloratadine [jan]
desloratadine [ema epar]
desloratadine [orange book]
desloratadine [usp-rs]
desloratadine [mart.]
loratadine impurity d [ep impurity]
rupatadine fumarate impurity b [ep impurity]
desloratadine component of clarinex-d
desloratadine [inn]
AB00456701-11
HY-B0539
4-(8-chloro-5,6-dihydro-11h-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene) piperidine
4-(8-chloro-5,6-dihydro-11h-benzo[5,6]cyclohepta(1,2-b]pyridin-11-ylidene)-piperidine
8-chloro-11-(4-piperidylidene)-6,11-dihydro-5h-benzo[5,6]cyclohepta[1,2-b]pyridine
4-(8-chloro-5,6-dihydro-11h-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine
4-(8-chloro-5,6-dihydro-11 h-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine
4-(8-chloro-5,6-dihydro-11h-benzo[5,6]cyclohepta [1,2-b]pyridin-11-ylidene) piperidine
4-{8-chloro-5,6-dihydro-11h-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene}piperidine
8-chloro-6,11-dihydro-11-(4-piperidinylidene)-5h-benzo[5,6]cyclohepta[1,2-b]pyridine
8-chloro-11-(4-piperidyliden)-6,11-dihydro-5h-benzo[5,6]cyclohepta[1,2-b]pyridine
8-chloro-6,11-dihydro-11-(4-piperidylidene)-5h-benzo[5,6]cyclohepta[1,2-b]pyridine
4-(8-chloro-5,6-dihydro-11h-benzo-[5,6]cyclohepta(1,2-b]pyridin-11-ylidene)-piperidine
8-chloro-11-(4-piperidyliden)-6,11-dihydro-5h-benzo[5,6]cyclohepta [1,2-b]pyridine
4-{8-chloro-5,6-dihydro-11h-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene}-piperidine
8-chloro-11-(4-piperidylidene)-6,11-dihydro-5h-benzo[5.6]cyclohepta[1,2-b]pyridine
NC00412
SCHEMBL4425
tox21_111574_1
NCGC00159325-05
KS-1048
AB00456701-13
Q-200936
OPERA_ID_1891
AB00456701_15
AB00456701_14
mfcd00871949
13-chloro-2-(piperidin-4-ylidene)-4-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaene
nsc 675447
sch34117
SR-01000668962-8
sr-01000668962
SR-01000668962-5
SR-01000668962-4
desloratadine, united states pharmacopeia (usp) reference standard
desloratadine, powder, >=98% (hplc)
HMS3652O15
H11943
desloratadine for system suitability, european pharmacopoeia (ep) reference standard
desloratadine, european pharmacopoeia (ep) reference standard
desloratidine, pharmaceutical secondary standard; certified reference material
SBI-0206828.P001
HMS3715J15
13-chloro-2-(piperidin-4-ylidene)-4-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaene
SW197792-3
Q418060
BCP02340
BRD-K82357231-001-13-4
SB17503
13-chloro-2-piperidin-4-ylidene-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaene
HMS3885C18
8-chloro-11-(4-piperidinylidene)-6,11-dihydro-5h- benzo[4,5]cyclohepta[2,1-b]pyridine
8-chloro-6,11-dihydro-11-(4-piperdinylidene)- 5h-benzo[5,6]cyclohepta[1,2-b]pyridine
8-chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5h-benzo[5,6]cyclohepta[1,2-b]pyridine (descarboethoxyloratadine; desloratadine)
desloratadine for system suitability
desloratadine- bio-x
BD164361
8-chloro-6,11-dihydro-11-(4-piperidinylidene)-5h-benzo[5,6]cyclohepta[1,2-b]pyridine-d5
8-chloro-6,11-dihydro-11-(4-piperidinylidene)-5h-benzo(5,6)cyclohepta(1,2-bpyridine
desloratadine (mart.)
rupatadine fumarate impurity b (ep impurity)
loratadine impurity d (ep impurity)
8-chloro-6,11-dihydro-11(4-piperidylidene)-5h-benzo(5,6)cyclohepta(1,2-b) pyridine
desloratadina
8-chloro-6,11-dihydro-11-(4-piperidinylidene)-5h-benzo(5,6)cyclohepta(1,2b)pyridine
r06ax27
desloratadine (ep monograph)
desloratadine (usp-rs)
desloratadine (usp monograph)
desloratadinum
8-chloro-11-piperidin-4-ylidene-6,11-dihydro-5h-benzo(5,6)cyclohepta(1,2-b)pyridine
13-chloro-2-(piperidin-4-ylidene)-4-azatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,12,14-hexaene
EN300-1589139
Z2235801903

Excerpt	Reference	Relevance
"1. Desloratadine is an antiallergic drug with species-dependent metabolic profiles in mice, rats, monkeys and humans. "	( Metabolism of desloratadine by chimeric TK-NOG mice transplanted with human hepatocytes. Higuchi, Y; Suemizu, H; Uehara, S; Yamazaki, H; Yoneda, N, 2020)	1.54
"Desloratadine is a frequently used drug for the treatment of allergic disorders, which often also require treatment during pregnancy. "	( Desloratadine Use During Pregnancy and Risk of Adverse Fetal Outcomes: A Nationwide Cohort Study. Andersen, JT; Andersson, NW; Poulsen, HE, 2020)	3.44
"Desloratadine is a drug with a phenotypic polymorphism in metabolism and has been approved for use in many countries to treat allergic diseases. "	( A Randomized Study on the Bioequivalence of Desloratadine in Healthy Chinese Subjects and the Association of Different Metabolic Phenotypes With UGT2B10 and CYP2C8 Genotypes. Dong, W; Fang, Y; Guo, D; Li, Y; Liu, G; Niu, S; Shen, T; Wang, J; Wang, Q; Xia, L; Zhang, M; Zhang, T, 2020)	2.26
"Desloratadine is a frequently used second-generation antihistamine considered to be effective and safe for the treatment of allergic diseases."	( Seizures induced by desloratadine, a second-generation antihistamine: clinical observations. Cerminara, C; Curatolo, P; El-Malhany, N; Lo Castro, A; Roberto, D, 2013)	1.43
"Desloratadine is a biologically active metabolite of second-generation antihistamine loratadine. "	( Safety evaluation of desloratadine in allergic rhinitis. González-Núñez, V; Mullol, J; Valero, A, 2013)	2.15
"Desloratadine is a novel, long-acting inhibitor of histamine."	( Effects of desloratadine citrate disodium injection on rat models of ovalbumin-induced allergic rhinitis: involvement of T-cell responses modulation. Ghosh, A; He, G; Jie, Q; Wu, Y; Yuan, X, 2015)	1.53
"Desloratadine is a biologically active metabolite of loratadine which is indicated for the treatment of allergic rhinitis. "	( The role of endothelin-1 and endothelin receptor antagonists in allergic rhinitis inflammation: ovalbumin-induced rat model. Halici, Z; Kose, D; Polat, E; Tatar, A; Yayla, M; Yoruk, O, 2016)	1.88
"Desloratadine is a non-sedating, long-acting histamine H(1) receptor antagonist indicated for the symptomatic relief of allergic rhinitis (AR) and chronic idiopathic urticaria in patients aged>12 years."	( Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Layton, D; Shakir, SA; Wilton, L, 2009)	2.04
"Desloratadine is a new non-sedating H1-receptor agonist."	( Desloratidine for the treatment of chronic urticaria. Monroe, EW, 2002)	1.04
"Desloratadine appears to be a "me-too" agent, with no major differences compared with other second-generation antihistamines."	( Desloratadine: a nonsedating antihistamine. Kockler, DR; Limon, L, 2003)	3.2
"Desloratadine is a well-tolerated and effective treatment of CIU."	( Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. Bernstein, D; Finn, A; Guerrero, R; Monroe, E; Patel, P; Ratner, P, 2003)	2.07
"Desloratadine is a systemic antihistamine indicated for the treatment of seasonal and perennial allergic rhinitis."	( Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo Crampton, HJ, 2003)	1.28
"Desloratadine is a potent, selective, histamine H(1)-receptor antagonist that does not easily cross the blood-brain barrier."	( Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements. de Halleux, F; Muntjewerff, ND; Ramaekers, JG; Rikken, GH; Vuurman, EF, 2004)	1.43
"Desloratadine is a non-sedating antihistamine recently approved for the treatment of seasonal allergic rhinitis. "	( Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of 3-hydroxydesloratadine. Alton, KB; Alvarez, N; Chowdhury, SK; Ghosal, A; Hapangama, N; Patrick, JE; Su, AD; Yuan, Y; Zbaida, S, 2004)	1.98
"Desloratadine is a selective H1-antihistamine used in the treatment of allergic rhinitis and chronic idiopathic urticaria. "	( Desloratadine prevents compound 48/80-induced mast cell degranulation: visualization using a vital fluorescent dye technique. Daly, AF; Harris, AG; Kreutner, W; Taché, Y; Wang, YH; Wei, JY, 2005)	3.21
"Desloratadine is a once-daily, non-sedating, non-impairing, selective histamine H1-receptor antagonist. "	( Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders. DuBuske, LM, 2005)	2.17
"Desloratadine is a once-daily oral antihistamine with a favourable sedation profile that is approved for the treatment of AR and CIU."	( Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety. Gupta, S; Kantesaria, B; Khalilieh, S; Kim, K; Lorber, R; Lutsky, B; Manitpisitkul, P; Prenner, B; Wang, Z, 2006)	1.32
"Desloratadine is an H1-histamine antagonist which possesses additional anti-inflammatory properties through inhibition of leukocyte activation and reduction of ICAM-1 expression on mucosal epithelial cells. "	( Impact of desloratadine and loratadine on the crosstalk between human keratinocytes and leukocytes: Implications for anti-inflammatory activity of antihistamines. Behrendt, H; Münster, I; Ring, J; Traidl-Hoffmann, C, 2006)	2.18
"Desloratadine is a potent antihistamine. "	( The effect of regular versus on-demand desloratadine treatment in children with allergic rhinitis. Adalioglu, G; Dizdar, EA; Dogan, C; Kalayci, O; Keskin, O; Sekerel, BE; Tuncer, A, 2007)	2.05
"Desloratadine is a rapid-acting, once-daily, nonsedating selective H1-receptor antagonist/inverse receptor agonist with proven clinical efficacy in patients with CIU."	( Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. DuBuske, L, 2007)	2.5
"Desloratadine was found to be a competitive antagonist (pA2 = 6.67+/-0.09) of carbachol-induced contractions in isolated rabbit iris smooth muscle."	( Anticholinergic effects of desloratadine, the major metabolite of loratadine, in rabbit and guinea-pig iris smooth muscle. Antón, F; Beleta, J; Cardelús, I; Palacios, JM, 1999)	1.32
"Desloratadine was shown to be a selective H1 antagonist with more potent antihistaminic activity in vitro than either loratadine or terfenadine (CAS 50679-08-8), as indicated by its displacement of 3H-mepyramine from H1 receptors in rat brain, guinea pig brain, and guinea pig lung, and by its antagonism of histamine-induced contractions of guinea pig ileum."	( Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Anthes, J; Barnett, A; Hey, JA; Kreutner, W; Tozzi, S; Young, S, 2000)	1.32
"Desloratadine is a novel, potent H1-receptor antagonist with additional inhibitory effects on inflammatory mediators such as cytokines and adhesion molecules."	( Desloratadine in the treatment of chronic idiopathic urticaria. Gauger, A; Hein, R; Ring, J, 2001)	2.47
"Desloratadine is a new agent for the treatment of diseases such as seasonal allergic rhinitis and chronic urticaria. "	( The pharmacologic profile of desloratadine: a review. Henz, BM, 2001)	2.04
"Desloratadine is a new, potent, nonsedating antihistamine that has an excellent cardiovascular safety profile."	( Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Bronsky, E; Gauger, A; Hein, R; Miller, B; Ring, J, 2001)	1.42
"Desloratadine 5 mg daily is a safe and effective treatment for CIU with significant benefits within 24 h and maintained through the treatment period."	( Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Bronsky, E; Gauger, A; Hein, R; Miller, B; Ring, J, 2001)	2.14
"Desloratadine is a new, selective, H(1)-receptor antagonist that also has anti-inflammatory activity. "	( Desloratadine: A new, nonsedating, oral antihistamine. Geha, RS; Meltzer, EO, 2001)	3.2
"Desloratadine is a biologically active metabolite of the second-generation antihistamine loratadine. "	( Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug. Agrawal, DK, 2001)	2.02
"Desloratadine is a non-sedating, clinically effective, anti-allergic therapy that has been shown to exhibit anti-inflammatory properties that extend beyond its ability to antagonize histamine at H(1)-receptor sites. "	( Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Kreutner, W; Lichtenstein, LM; Schleimer, RP; Schroeder, JT, 2001)	1.98
"Desloratadine is a new treatment option for patients with IAR and nasal congestion."	( Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Nayak, AS; Schenkel, E, 2001)	2.47

Excerpt	Reference	Relevance
"Desloratadine has a half-life of 21-24 h, permitting once-daily dosing."	( The pharmacologic profile of desloratadine: a review. Henz, BM, 2001)	1.32
"Desloratadine has an excellent overall safety profile."	( Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug. Agrawal, DK, 2001)	1.3
"Desloratadine has no effect in attenuating the broncho-constriction caused by exercise in patients with allergic rhinitis and exercise induced broncho-constriction."	( Effect of desloratadine on patients with allergic rhinitis and exercise-induced bronchoconstriction: a placebo controlled study. Maharaj, B; Manjra, AI; Nel, H, 2009)	2.2
"Desloratadine has demonstrated efficacy in treating SAR symptoms, including nasal obstruction."	( Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. Baena-Cagnani, CE; Berger, WE; Danzig, M; DuBuske, LM; Gurné, SE; Lorber, R; Stryszak, P, 2003)	1.35
"Desloratadine has been approved by the European Medicines Evaluation Agency for the treatment of intermittent and persistent AR, as defined by the ARIA classification."	( Desloratadine treatment for intermittent and persistent allergic rhinitis: a review. Bachert, C; van Cauwenberge, P, 2007)	2.5
"Desloratadine has been found to be effective and well tolerated in studies in subjects with symptoms of AR analogous to/consistent with the ARIA definitions of intermittent and persistent disease. "	( Desloratadine treatment for intermittent and persistent allergic rhinitis: a review. Bachert, C; van Cauwenberge, P, 2007)	3.23
"Desloratadine has a half-life of 21-24 h, permitting once-daily dosing."	( The pharmacologic profile of desloratadine: a review. Henz, BM, 2001)	1.32
"Desloratadine has an excellent overall safety profile."	( Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug. Agrawal, DK, 2001)	1.3

Excerpt	Reference	Relevance
"Desloratadine caused an increase in the total antioxidant status level, but it was not statistically significant."	( Influence of desloratadine on selected oxidative stress markers in patients between 3 and 10 years of age with allergic perennial rhinitis. Bieszczad-Bedrejczuk, E; Rachel, M; Sadowska-Woda, I, 2010)	1.45
"Desloratadine does not cause sedation or prolong the corrected QT (QTc) interval, can be administered without regard to concurrent intake of food and grapefruit juice, and appears to have negligible potential for drug interactions mediated by several metabolic systems."	( Desloratadine: an update of its efficacy in the management of allergic disorders. Goa, KL; Keam, SJ; Murdoch, D, 2003)	2.48
"Desloratadine displays linear pharmacokinetics after oral administration."	( Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. DuBuske, L, 2007)	2.5
"Desloratadine did not inhibit IKr channel human ether-a-go-go-related gene (HERG)-induced current in a study in which HERG was expressed in Xenopus oocytes."	( Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 2nd communication: lack of central nervous system and cardiovascular effects. Barnett, A; Chiu, P; Hey, JA; Kreutner, W, 2000)	1.32

Excerpt	Reference	Relevance
"Desloratadine treatment decreased cell viability of U251 human glioblastoma cell line and primary human glioblastoma cell culture (IC50 value 50 µM) by an increase of intracellular reactive oxygen species and caspase activity."	( Proapoptotic and proautophagy effect of H1-receptor antagonist desloratadine in human glioblastoma cell lines. Grujicic, D; Ilic, R; Isakovic, A; Karapandza, K; Martinovic, T; Raicevic, S; Stanojevic, Z; Tasic, J; Tomonjic, N; Vidicevic-Novakovic, S; Zekovic, J, 2023)	1.87
"Desloratadine treatment alleviated AR symptoms, decreased serum level of OVA-specific IgE and IL-17 in AR rats."	( Desloratadine Ameliorates Olfactory Disorder and Suppresses AMPA Receptor GluA1 Expression in Allergic Rhinitis Rat. Huang, Y; Jiang, X; Jiang, Y; Li, N; Li, S; Li, Z; Zhang, J; Zhang, N; Zhang, X; Zhao, H, 2020)	2.72
"All desloratadine-treated patients (n = 360) were included in this exploratory analysis."	( Randomized controlled trial of desloratadine for persistent allergic rhinitis: correlations between symptom improvement and quality of life. Bousquet, J; Canonica, GW; Fokkens, WJ; Gopalan, G; Shekar, T; Zuberbier, T, )	0.9
"Desloratadine treatment was associated with less deterioration from baseline in the mean nasal airflow (P < 0.05) and in the mean severity score for the symptom of nasal obstruction (P < 0.03)."	( Impact and modulation of nasal obstruction. Horak, F, 2002)	1.04
"Desloratadine treatment during allergen exposure reduced allergic symptoms and reduced sinonasal infection (P<0.05)."	( Desloratadine partially inhibits the augmented bacterial responses in the sinuses of allergic and infected mice. Blair, C; Kirtsreesakul, V; Naclerio, RM; Thompson, K; Yu, X, 2004)	2.49
"Desloratadine treatment during nasal challenge inhibited allergic symptoms and reduced sinonasal infection, suggesting that histamine via an H1 receptor plays a role in the augmented infection in mice with an ongoing allergic reaction."	( Desloratadine partially inhibits the augmented bacterial responses in the sinuses of allergic and infected mice. Blair, C; Kirtsreesakul, V; Naclerio, RM; Thompson, K; Yu, X, 2004)	3.21
"Desloratadine treatment was no different than placebo."	( Effect of combined montelukast and desloratadine on the early asthmatic response to inhaled allergen. Cockcroft, DW; Davis, BE; Todd, DC, 2005)	1.33
"Desloratadine treatment for 14 days improved nasal airflow and resistance as well as symptom and QOL scores in patients with symptomatic SAR during the allergy season."	( Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: results of a single-center, placebo-controlled trial. Harris, AG; Iezzoni, D; Jalowayski, AA; Meltzer, EO; Vogt, K, 2006)	2.18
"Desloratadine treatment was associated with significant improvements compared with placebo in pruritus scores and in the size of the largest wheals as early as day 1. "	( Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. Auquier, P; Dreyfus, I; Grob, JJ; Ortonne, JP, 2007)	2.09
"Desloratadine treatment was associated with significantly greater improvements from baseline to day 42 compared with placebo in DLQI overall score (-6 vs."	( Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, multicentre, placebo-controlled study. Auquier, P; Dreyfus, I; Grob, JJ; Ortonne, JP, 2008)	1.3
"Desloratadine is a new treatment option for patients with IAR and nasal congestion."	( Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Nayak, AS; Schenkel, E, 2001)	2.47
"Treatment with desloratadine 5 mg daily for 7 days reduced allergic ocular symptoms following allergen challenge."	( Evaluation of desloratadine on conjunctival allergen challenge-induced ocular symptoms. Gomes, P; Gopalan, G; Srinivasan, S; Torkildsen, GL; Welch, D, 2009)	1.07
"Treatment with desloratadine dominated placebo (cost less and resulted in greater effectiveness) for all measures of effectiveness. "	( The cost-effectiveness of treatment with desloratadine in patients with persistent allergic rhinitis. Lorber, R; Navaratnam, P; Shekar, T; Sullivan, PW, 2010)	0.98
"The treatment with desloratadine normalized the superoxide dismutase and catalase activity as well as the malondialdehyde formation."	( Influence of desloratadine on selected oxidative stress markers in patients between 3 and 10 years of age with allergic perennial rhinitis. Bieszczad-Bedrejczuk, E; Rachel, M; Sadowska-Woda, I, 2010)	1.05
"Treatment with desloratadine caused a relevant reduction of ROS levels and SOD activity (P<0.005)."	( Influence of desloratadine on oxidative stress markers in patients with chronic idiopathic urticaria. Amoruso, A; Cassano, N; D'Argento, V; Filieri, M; Filotico, R; Raho, G; Vena, GA, 2006)	1.04

Excerpt	Reference	Relevance
" The most common adverse event for all regimens was headache, reported in 20 (22%) subjects."	( Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Affrime, M; Banfield, C; Batra, V; Clement, R; Gupta, S; Kantesaria, B; Marino, M, 2001)	0.58
" Desloratadine was safe and well tolerated; adverse events were similar to placebo overall."	( Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Berger, WE; Mansfield, LE; Schenkel, EJ, 2002)	1.54
"We hypothesized that desloratadine, a new, nonsedating selective H1-antihistamine, would be efficacious and safe in the treatment of perennial allergic rhinitis."	( Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. Finn, A; Prenner, BM; Simons, FE, 2003)	0.95
" Dropouts, and the type and frequency of adverse events (headache, viral infection, pharyngitis, and upper respiratory tract infection), were similar in both treatment groups."	( Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. Finn, A; Prenner, BM; Simons, FE, 2003)	0.63
" The incidence of adverse events, including somnolence, was similar in the desloratadine and placebo groups."	( Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. Bernstein, D; Finn, A; Guerrero, R; Monroe, E; Patel, P; Ratner, P, 2003)	0.86
" Desloratadine, an oral non-sedating antihistamine, has been shown in multiple studies to be safe and effective in relieving the symptoms of AR and chronic idiopathic urticaria (CIU) in adults and adolescents."	( Safety of desloratadine syrup in children. Bloom, M; Herron, J; Staudinger, H, 2004)	1.64
" Safety evaluations included adverse event report collection, monitoring of vital signs, clinical laboratory measurements, and standard 12-lead electrocardiogram (ECG) measurements."	( Safety of desloratadine syrup in children. Bloom, M; Herron, J; Staudinger, H, 2004)	0.73
"In the study involving subjects aged 2 years-5 years (n = 111), the incidence of adverse events was 7/55 for the group treated with desloratadine and 6/56 for placebo."	( Safety of desloratadine syrup in children. Bloom, M; Herron, J; Staudinger, H, 2004)	0.93
" No unusual or unexpected adverse events were reported."	( Efficacy and safety of an extended-release formulation of desloratadine and pseudoephedrine vs the individual components in the treatment of seasonal allergic rhinitis. Grubbe, R; Lutsky, B; Pleskow, W; Weiss, S, 2005)	0.57
" Although first-generation antihistamines can cause sedation and cognitive impairment, second-generation antihistamines are relatively non-sedating and free of such adverse events owing to their comparative inability to penetrate the blood-brain barrier."	( The safety and efficacy of desloratadine for the management of allergic disease. Berger, WE, 2005)	0.63
" The most frequently reported adverse events were insomnia, headache, and dry mouth."	( Efficacy and safety of desloratadine/pseudoephedrine tablet, 2.5/120 mg two times a day, versus individual components in the treatment of patients with seasonal allergic rhinitis. Chervinsky, P; Danzig, M; Nayak, A; Rooklin, A, )	0.44
" Adverse events occurred with similar frequency among desloratadine- and placebo-treated patients."	( Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. Auquier, P; Dreyfus, I; Grob, JJ; Ortonne, JP, 2007)	0.9
" Eleven treatment-related adverse events, all mild to moderate in severity, were reported."	( Multiple-dose pharmacokinetics and safety of desloratadine in subjects with moderate hepatic impairment. Gupta, SK; Kantesaria, B; Wang, Z, 2007)	0.6
" The efficiency and side-effect were evaluated at the end of treatment."	( Efficacy and safety of desloratadine combined with dipyridamole in the treatment of chronic urticaria. Abdalla, AN; Khalaf, AT; Liu, XM; Sheng, WX; Tan, JQ, 2008)	0.66
"Aerius is safe and can effectively reduction in nasal and nonnasal symptoms in patients with seasonal allergic rhinitis."	( [The investigation of efficacy and safety of Aerius to seasonal allergic rhinitis]. Cui, Y; Gao, Q; Liu, Z; Xu, K; You, X, 2008)	0.35
" Tolerability was based on the recording of adverse events (AEs), physical examination, electrocardiograms, and laboratory screen controls at baseline and the final study visit."	( Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study. Antonijoan, R; Barbanoj, M; Carbó, ML; Donado, E; Izquierdo, I; Merlos, M; Nadal, T; Peña, J; Solans, A, 2008)	0.35
" The incidence of treatment emergent adverse events was similar for bilastine (20."	( Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Bachert, C; Dimitrov, V; Gorina, MM; Ivan, P; Kuna, P; Loureiro, A; Sanquer, F; van de Heyning, P, 2009)	0.6
"Bilastine 20 mg once daily was efficacious, safe and not different from desloratadine 5 mg once daily in the treatment of SAR symptoms."	( Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Bachert, C; Dimitrov, V; Gorina, MM; Ivan, P; Kuna, P; Loureiro, A; Sanquer, F; van de Heyning, P, 2009)	0.83
" Adverse events reported during or < or = 30 days after treatment were collected."	( Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients. Augustin, M; Ehrle, S, 2009)	0.66
" The incidence of adverse events was low (0."	( Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients. Augustin, M; Ehrle, S, 2009)	0.66
" Second-generation antihistamines have become increasingly popular because of their comparable efficacy and lower incidence of adverse effects relative to their first-generation counterparts, and the safety and efficacy of this drug class are established in the adult population."	( Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. Moeller, ML; Nahata, MC; Phan, H, 2009)	0.35
" Adverse events (AEs) were reported throughout the studies; serious AEs were recorded for up to 30 days after treatment."	( Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. Bachert, C; Maurer, M, 2010)	0.67
" Desloratadine is highly selective for histamine H₁-receptors, does not cross the blood-brain barrier (BBB), and has minimal adverse events (very low sedation rate), with a better safety and tolerability than first-generation antihistamines."	( Safety evaluation of desloratadine in allergic rhinitis. González-Núñez, V; Mullol, J; Valero, A, 2013)	1.62
" Loratadine and desloratadine residues have been found at very low concentrations (ng/L) in the aquatic environment but their toxic effects are still not well known."	( Ecotoxic effects of loratadine and its metabolic and light-induced derivatives. Cermola, F; DellaGreca, M; Iesce, MR; Isidori, M; Lavorgna, M; Passananti, M; Piscitelli, C; Russo, C; Temussi, F, 2019)	0.86
" However, desloratadine induces various degrees of sedation side effect in CSU patients, and no biomarkers currently exist for predicting the severity of such side effect."	( Human H1 receptor (HRH1) gene polymorphism is associated with the severity of side effects after desloratadine treatment in Chinese patients with chronic spontaneous uticaria. Chen, W; Chen, X; Li, J; Liu, Z; Peng, C; Su, J; Zhang, W; Zhu, W, 2020)	1.18
"A small number of adverse events of seizure in patients using desloratadine (DL) have been reported."	( Desloratadine Exposure and Incidence of Seizure: A Nordic Post-authorization Safety Study Using a New-User Cohort Study Design, 2001-2015. Aas, E; Aasbjerg, K; Bolin, K; Born, AP; Brady, JE; Emneus, M; Ersbøll, AK; Gislason, G; Kjærulff, TM; Mines, D; Pukkala, E; Ramey, DR; Sengupta, K; Vestergaard, C, 2021)	2.3

Excerpt	Reference	Relevance
" Loratadine was rapidly absorbed and the decline of plasma concentrations after attainment of the Cmax was biexponential in all subjects."	( Pharmacokinetics of loratadine in patients with renal insufficiency. Halstenson, CE; Hilbert, J; Matzke, GR; Opsahl, JA; Perentesis, G; Radwanski, E; Zampaglione, N, 1990)	0.28
" Concentrations of loratadine in the disposition phase were fitted to a biexponential equation and those of descarboethoxyloratadine to either a monoexponential or biexponential equation for pharmacokinetic analysis."	( The pharmacokinetics of loratadine in normal geriatric volunteers. Hilbert, J; Moritzen, V; Parks, A; Perentesis, G; Radwanski, E; Symchowicz, S; Zampaglione, N, )	0.13
" A single-dose, open-label bioavailability study was performed to characterize the pharmacokinetic profiles of loratadine and its metabolite desloratadine."	( The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 years. Affrime, MB; Banfield, C; Herron, JM; Lorber, R; Padhi, D; Salmun, LM, 2000)	0.51
"This study was undertaken to assess the effects of coadministration of desloratadine or fexofenadine with azithromycin on pharmacokinetic parameters, tolerability, and electrocardiographic (ECG) findings."	( Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Affrime, M; Banfield, C; Batra, V; Clement, R; Gupta, S; Kantesaria, B; Marino, M, 2001)	0.81
"The results of the pharmacokinetic analysis revealed little change in mean maximum concentration (Cmax) and area under the concentration-time curve (AUC) values for desloratadine with concomitant administration of azithromycin: Cmax ratio, 115% (90% CI, 92-144); AUC, ratio 105% (90% CI, 82-134)."	( Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Affrime, M; Banfield, C; Batra, V; Clement, R; Gupta, S; Kantesaria, B; Marino, M, 2001)	0.78
"To characterise the pharmacokinetic profile of desloratadine and its main metabolite, 3-hydroxy (3-OH) desloratadine, in a patient population representative of the population studied in the desloratadine clinical efficacy and safety studies, including the elderly."	( A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Affrime, M; Banfield, C; Cohen, A; Gupta, S, 2002)	0.86
"A multicentre, multidose, open-label pharmacokinetic trial."	( A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Affrime, M; Banfield, C; Cohen, A; Gupta, S, 2002)	0.61
" There were no clinically relevant differences in the calculated pharmacokinetic parameters of desloratadine when participants were stratified into 3 age groups (19 to 45, 46 to 64 and 65 to 70 years)."	( A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Affrime, M; Banfield, C; Cohen, A; Gupta, S, 2002)	0.82
" The 27-hour half-life of desloratadine permits once daily administration."	( A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Affrime, M; Banfield, C; Cohen, A; Gupta, S, 2002)	0.91
"This study was designed to characterise the single and multiple dose pharmacokinetic profile of desloratadine, a new antihistamine, and its main metabolite, 3-hydroxy (3-OH) desloratadine, in healthy volunteers differing in sex and race."	( Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. Affrime, M; Banfield, C; Boutros, T; Cayen, M; Cohen, A; Gupta, S; Thonoor, M, 2002)	0.77
"An open-label, parallel-group, single- and multiple-dose pharmacokinetic trial."	( Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. Affrime, M; Banfield, C; Boutros, T; Cayen, M; Cohen, A; Gupta, S; Thonoor, M, 2002)	0.55
" The apparent elimination half-life (T1/2) of LOR was (6+/-4) h, and that of DCL was (13."	( Pharmacokinetics of loratadine and its active metabolite descarboethoxyloratadine in healthy Chinese subjects. Chen, XY; Dong, YM; Zhang, YF; Zhong, DF, 2003)	0.32
"This study determined the pharmacokinetic profile of single-dose loratadine-ambroxol hydrochloride combination therapy versus each component given separately."	( Pharmacokinetic properties of single-dose loratadine and ambroxol alone and combined in tablet formulations in healthy men. Alcántar, F; Herrera, J; Morales, JM; Rodríguez, JM; Rosete, R; Villacampa, J, 2003)	0.32
" Coadministration of desloratadine with a potent inhibitor of CYP2D6 did not result in clinically relevant changes in its pharmacokinetic parameters."	( Pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers. Banfield, C; Flannery, B; Gupta, S; Herron, J; Kantesaria, B, 2004)	0.92
" In view of the large interindividual variability in loratadine pharmacokinetics and the greater genetically determined variability of CYP2D6 activity than of CYP3A4 in vivo, we hypothesized that CYP2D6 polymorphisms may contribute to the pharmacokinetic variability of loratadine."	( Effect of cyp2d6*10 allele on the pharmacokinetics of loratadine in chinese subjects. Chow, MS; Shi, XJ; Tomlinson, B; Yin, OQ, 2005)	0.33
" It is concluded that estimating in vivo receptor occupancy, which takes into account both the affinity of the drug for the receptor and its free plasma concentration, is a far better predictor for human pharmacodynamics and hence antihistamine potency, than considering in vitro affinity and plasmatic half-life only."	( Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines. Baltes, E; Benedetti, MS; Chatelain, P; Gillard, M, 2005)	0.33
" Subjects were given desloratadine 5 mg once daily for 10 days and were assessed in several pharmacokinetic parameters."	( Multiple-dose pharmacokinetics and safety of desloratadine in subjects with moderate hepatic impairment. Gupta, SK; Kantesaria, B; Wang, Z, 2007)	0.92
" The method was shown to be accurate, rapid and sufficiently sensitive to be successfully applied to a pharmacokinetic and bioequivalent study."	( Simultaneous determination of desloratadine and its active metabolite 3-hydroxydesloratadine in human plasma by LC/MS/MS and its application to pharmacokinetics and bioequivalence. Chen, WL; Chu, NN; Li, XN; Xu, HR, 2007)	0.63
" Except for maximum observed concentration during a dosing interval (Cmax,ss) of 3-hydroxydesloratadine, on average, there were no statistically significant differences in mean plasma concentrations in any of the main pharmacokinetic parameters of rupatadine, desloratadine, and 3-hydroxydesloratadine when administered in combination with azithromycin or alone."	( Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study. Antonijoan, R; Barbanoj, M; Carbó, ML; Donado, E; Izquierdo, I; Merlos, M; Nadal, T; Peña, J; Solans, A, 2008)	0.57
" The method has been successfully applied to a pharmacokinetic study of rupatadine and its major metabolite after oral administration of 10, 20 and 40mg rupatadine tablets to healthy Chinese volunteers."	( Simultaneous determination of rupatadine and its metabolite desloratadine in human plasma by a sensitive LC-MS/MS method: application to the pharmacokinetic study in healthy Chinese volunteers. Fan, G; Hong, Z; Wei, H; Wen, J; Wu, Y, 2009)	0.6
" The pharmacokinetic profiles were analyzed using a non-compartmental method in the Phoenix WinNonlin program."	( Prevalence of Desloratadine Slow-metabolizer Phenotype and Food-dependent Pharmacokinetics of Desloratadine in Healthy Chinese Volunteers. He, L; Jiang, X; Li, T; Wang, L; Wang, T; Xie, H; Zhang, K, 2015)	0.78
"The accuracy of physiologically based pharmacokinetic (PBPK) model prediction in children, especially those younger than 2 years old, has not been systematically evaluated."	( Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children. Al-Huniti, N; Bui, KH; Cheung, SYA; Johnson, TN; Li, J; Xu, H; Zhou, D; Zhou, W, 2018)	0.48
" The drug dissolution and the gastrointestinal tract pH conditions are likely to influence the in vivo pharmacokinetic behavior of LTD tablets."	( Simultaneous Determination of Loratadine and Its Metabolite Desloratadine in Beagle Plasma by LC-MS/MS and Application for Pharmacokinetics Study of Loratadine Tablets and Omeprazole‑Induced Drug-Drug Interaction. Li, X; Wang, W; Wang, Y; Wu, W; Xu, Q; Zhang, J; Zhang, T; Zhang, Y, 2021)	0.86
" Pharmacokinetic results showed in the fasting state the three LTD tablets were equivalent in beagles in terms of effective components."	( Simultaneous Determination of Loratadine and Its Metabolite Desloratadine in Beagle Plasma by LC-MS/MS and Application for Pharmacokinetics Study of Loratadine Tablets and Omeprazole‑Induced Drug-Drug Interaction. Li, X; Wang, W; Wang, Y; Wu, W; Xu, Q; Zhang, J; Zhang, T; Zhang, Y, 2021)	0.86

Excerpt	Reference	Relevance
" A substantial increase was observed in mean Cmax and AUC values for fexofenadine when administered with azithromycin: Cmax, ratio, 169% (90% CI, 120-237); AUC ratio, 167% (90% CI, 122-229)."	( Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Affrime, M; Banfield, C; Batra, V; Clement, R; Gupta, S; Kantesaria, B; Marino, M, 2001)	0.58
" Our study was done to evaluate the clinical efficacy and safety of desloratadine combined with dipyridamole, which is a platelet adhesion inhibitor in the treatment of CU."	( Efficacy and safety of desloratadine combined with dipyridamole in the treatment of chronic urticaria. Abdalla, AN; Khalaf, AT; Liu, XM; Sheng, WX; Tan, JQ, 2008)	0.89
" Except for maximum observed concentration during a dosing interval (Cmax,ss) of 3-hydroxydesloratadine, on average, there were no statistically significant differences in mean plasma concentrations in any of the main pharmacokinetic parameters of rupatadine, desloratadine, and 3-hydroxydesloratadine when administered in combination with azithromycin or alone."	( Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study. Antonijoan, R; Barbanoj, M; Carbó, ML; Donado, E; Izquierdo, I; Merlos, M; Nadal, T; Peña, J; Solans, A, 2008)	0.57
"Montelukast alone or in combination with antihistamines gave a gradual increase in nasal symptom improvement within 6 weeks of treatment in patients with persistent AR."	( Use of montelukast alone or in combination with desloratadine or levocetirizine in patients with persistent allergic rhinitis. Barylski, M; Ciebiada, M; Gorska-Ciebiada, M; Gorski, P; Kmiecik, T, )	0.39
" In vitro assessment of the proarrhythmic potential of drugs is limited to one compound and thus neglects the potential of drug-drug interactions, including those involving active metabolites."	( Drug interaction at hERG channel: In vitro assessment of the electrophysiological consequences of drug combinations and comparison against theoretical models. Kulig, M; Lisowski, B; Polak, S; Wiśniowska, B, 2018)	0.48
"To analyze the efficacy and safety of Tripterygium Glycosides Tablets combined with desloratadine as well as desloratadine alone in the treatment of chronic urticaria by Meta-analysis,in order to provide evidence-based reference for clinical treatment."	( [Meta-analysis of efficacy and safety of Tripterygium Glycosides Tablets combined with desloratadine in treatment of chronic urticarial]. Pang, GX; Qiu, XJ; Shi, YS; Wang, QM, 2019)	0.96
"This experiment was performed to explore the effect of oral desloratadine citrate disodium combined with physiological seawater nasal irrigation in the treatment of intermittent allergic rhinitis and its effect on serum inflammatory factors and peripheral blood Th1 and Th2."	( Effects of oral desloratadine citrate disodium combined with physiological seawater nasal irrigation on IgE levels, IL-4, IL-6, IL-13 and IFN-γ expression and treatment of intermittent allergic rhinitis. Li, W; Zhang, Y, 2020)	1.15
"We sought to evaluate the efficacy and clinical feasibility of desloratadine in combination with compound glycyrrhizin in the treatment of CU."	( Efficiency and safety of desloratadine in combination with compound glycyrrhizin in the treatment of chronic urticaria: a meta-analysis and systematic review of randomised controlled trials. Lai, Y; Li, M; Tang, Y; Wen, Y, 2021)	1.16
" A comparative pharmacokinetics study of three LTD tablets with different dissolution rates was conducted in male beagles in fasting state and an omeprazole-induced drug-drug interaction (DDI) study was subsequently performed under pretreatment of omeprazole."	( Simultaneous Determination of Loratadine and Its Metabolite Desloratadine in Beagle Plasma by LC-MS/MS and Application for Pharmacokinetics Study of Loratadine Tablets and Omeprazole‑Induced Drug-Drug Interaction. Li, X; Wang, W; Wang, Y; Wu, W; Xu, Q; Zhang, J; Zhang, T; Zhang, Y, 2021)	0.86
" Moreover, significant changes in LTD and DL pharmacokinetics parameters were observed under the effect of omeprazole-induced pH increase in gastrointestinal tract, suggesting that DDI effects are of concern for the curative effect of LTD when combined with omeprazole."	( Simultaneous Determination of Loratadine and Its Metabolite Desloratadine in Beagle Plasma by LC-MS/MS and Application for Pharmacokinetics Study of Loratadine Tablets and Omeprazole‑Induced Drug-Drug Interaction. Li, X; Wang, W; Wang, Y; Wu, W; Xu, Q; Zhang, J; Zhang, T; Zhang, Y, 2021)	0.86
"To investigate the efficacy of desloratadine citrate combined with compound glycyrrhizin in the treatment of subacute eczema."	( Desloratadine citrate combined with compound glycyrrhizin in the treatment of subacute eczema: A randomized trial. Chen, C; Wang, G; Xu, X; Yang, J; Ye, A, 2022)	2.45

Excerpt	Reference	Relevance
" A single-dose, open-label bioavailability study was performed to characterize the pharmacokinetic profiles of loratadine and its metabolite desloratadine."	( The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 years. Affrime, MB; Banfield, C; Herron, JM; Lorber, R; Padhi, D; Salmun, LM, 2000)	0.51
" In clinical studies, oral desloratadine is rapidly absorbed and bioavailability is not affected by ingestion with food or grapefruit juice."	( Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug. Agrawal, DK, 2001)	0.88
"Certain foods, such as grapefruit juice, are known to substantially alter the bioavailability of some drugs."	( Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Affrime, M; Banfield, C; Gupta, S; Lim, J; Marino, M, 2002)	0.55
"To assess the effect of consumption of grapefruit juice on the oral bioavailability of two nonsedating antihistamines, fexofenadine and desloratadine."	( Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Affrime, M; Banfield, C; Gupta, S; Lim, J; Marino, M, 2002)	0.75
" In contrast, the bioavailability of desloratadine was unaffected by grapefruit juice."	( Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Affrime, M; Banfield, C; Gupta, S; Lim, J; Marino, M, 2002)	0.82
"The bioavailability of drugs that do not undergo significant intestinal or hepatic metabolism, such as fexofenadine, may be altered when administered with agents that influence drug transport mechanisms."	( Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Affrime, M; Banfield, C; Gupta, S; Lim, J; Marino, M, 2002)	0.55
"To determine the effect of coadministration of food on the bioavailability of oral desloratadine."	( Oral bioavailability of desloratadine is unaffected by food. Affrime, M; Banfield, C; Glue, P; Gupta, S; Marbury, T; Padhi, D, 2002)	0.85
"In this population of healthy mate volunteers, results showed the bioavailability of loratadine and ambroxol from the new formulation and did not show impairment of absorption when the drugs were formulated in a combination tablet."	( Pharmacokinetic properties of single-dose loratadine and ambroxol alone and combined in tablet formulations in healthy men. Alcántar, F; Herrera, J; Morales, JM; Rodríguez, JM; Rosete, R; Villacampa, J, 2003)	0.32
" The absolute bioavailability is 50-65% for mizolastine; it is high for levocetirizine as the percentage of the drug eliminated unchanged in the 48 h urine is 77% of the oral dose; the estimation for fexofenadine is at least 33%; no estimation was found for desloratadine."	( Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Benedetti, MS; Diquet, B; Molimard, M, 2004)	0.76
"The purpose of this study was to describe the effect of the concomitant intake of food on the pharmacokinetic profile and bioavailability of a single dose of rupatadine."	( Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study. Carbó, ML; Izquierdo, I; Merlos, M; Nadal, T; Peña, J; Solans, A, 2007)	0.34
" Age and sex have no apparent effect on the drug's metabolism and elimination, and food does not affect its bioavailability or absorption."	( Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. DuBuske, L, 2007)	1.78
" No major cytochrome P450 inhibition has been reported with desloratadine, fexofenadine and levocetirizine, and the bioavailability of desloratadine is minimally affected by drugs interfering with transporter molecules."	( Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. Devillier, P; Faisy, C; Roche, N, 2008)	0.84
" The 90% CIs were included in the interval 80% to 125% for desloratadine and 3-hydroxydesloratadine, whereas 90% CI for rupatadine was shifted to the right of the interval used for comparing bioavailability of the drugs."	( Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study. Antonijoan, R; Barbanoj, M; Carbó, ML; Donado, E; Izquierdo, I; Merlos, M; Nadal, T; Peña, J; Solans, A, 2008)	0.59
"Solid dispersion systems have been widely used to enhance dissolution rate and oral bioavailability of poorly water-soluble drugs."	( Spray coating as a powerful technique in preparation of solid dispersions with enhanced desloratadine dissolution rate. Djuriš, J; Grujić, B; Homšek, I; Ibrić, S; Kachrimanis, K; Kolašinac, N, 2013)	0.61
"The absorption rate of montelukast was not altered when administered with desloratadine."	( Does desloratadine alter the serum levels of montelukast when administered in a fixed-dose combination? Cakli, H; Cingi, C; Erdogmus, N; Ertugay, CK; Gurbuz, MK; Ince, I; Karasulu, E; Kaya, E; Toros, SZ, 2013)	1.13
"Taken together, these results indicated that the incidence of the DSM phenotype in the Chinese population was low and that food intake could significantly decrease the absorption rate and extent of desloratadine."	( Prevalence of Desloratadine Slow-metabolizer Phenotype and Food-dependent Pharmacokinetics of Desloratadine in Healthy Chinese Volunteers. He, L; Jiang, X; Li, T; Wang, L; Wang, T; Xie, H; Zhang, K, 2015)	0.97
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Combined with borderline bioavailability and not really known fraction of absorbed dose, desloratadine was found to be a good example for showing the innovative in vitro approaches necessary to unambiguously classify desloratadine according to Biopharmaceutical Classification System (BCS) guideline."	( Biopharmaceutical classification of desloratadine - not all drugs are classified the easy way. Berginc, K; Legen, I; Sibinovska, N; Trontelj, J; Žakelj, S, 2020)	1.05

Excerpt	Relevance	Reference
"0 hour after dosing and the milk Cmax was 29."	( Excretion of loratadine in human breast milk. Affrime, MB; Hilbert, J; Perentesis, G; Radwanski, E; Symchowicz, S; Zampaglione, N, 1988)	0.27
" The drug had no adverse cardiovascular effects in various animal models or when administered at 9 times the recommended adult dosage for 10 days in volunteers."	( Desloratadine. Jarvis, B; McClellan, K, 2001)	1.75
" No dosage adjustment of desloratadine is required in the elderly."	( A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Affrime, M; Banfield, C; Cohen, A; Gupta, S, 2002)	0.91
" Comparison of the C(max) and AUC values following 14 days of treatment with desloratadine indicates that no dosage adjustment is needed on the basis of sex or race."	( Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. Affrime, M; Banfield, C; Boutros, T; Cayen, M; Cohen, A; Gupta, S; Thonoor, M, 2002)	0.78
" It has a rapid onset of effect, efficacy throughout a 24-hour dosage interval, and sustained efficacy in these allergic conditions, as demonstrated in placebo-controlled trials of up to 6 weeks' duration in adult and adolescent patients."	( Desloratadine: an update of its efficacy in the management of allergic disorders. Goa, KL; Keam, SJ; Murdoch, D, 2003)	1.76
" First, we constructed a dose-response curve."	( Acute bacterial rhinosinusitis causes hyperresponsiveness to histamine challenge in mice. Kirtsreesakul, V; Klemens, JJ; Luxameechanporn, T; Naclerio, RM, 2005)	0.33
"Desloratadine was determined in two dosage forms (tablets and syrup) with the use of the method of capillary isotachophoresis."	( [Isotachophoretic determination of desloratadine in tablets and syrup]. Havránek, E; Kubacák, P; Mikus, P; Valásková, I, 2005)	2.05
"05) inhibited by a dose-response of DL compared with positive controls, in both NM (10(-5) m: 125+/-36 pg/mL, 10(-6) m: 95+/-22 pg/mL vs."	( Effect of desloratadine on epithelial cell granulocyte-macrophage colony-stimulating factor secretion and eosinophil survival. Alobid, I; Bernal-Sprekelsen, M; Mullol, J; Picado, C; Pujols, L; Roca-Ferrer, J; Valero, A; Xaubet, A, 2006)	0.74
"Twelve healthy male volunteers participated in a four-period cross-over trial evaluating the effect of dosage forms on the pharmacokinetics of a single dose of loratadine."	( The relative bioavailability of loratadine administered as a chewing gum formulation in healthy volunteers. Bidstrup, TB; Brosen, K; Damkier, P; Nielsen, F; Noehr-Jensen, L; Pedersen, RS, 2006)	0.33
" Its action is sustained over the 24-hour dosing interval."	( Effect of desloratadine on the control of morning symptoms in patients with seasonal and perennial allergic rhinitis. Schenkel, EJ, )	0.53
"0 h after dosing in both age groups."	( Pharmacokinetics of desloratadine in children between 2 and 11 years of age. Banfield, C; Gupta, S; Kantesaria, B; Khalilieh, S, 2007)	0.66
"Inter- and intra-individual variability of the loratadine (LOR) metabolism in Caucasian subjects was assessed during a bioequivalence study for two pharmaceutical formulations (solid oral dosage forms) containing 10 mg of the active substance."	( Validated ion pair liquid chromatography/fluorescence detection method for assessing the variability of the loratadine metabolism occurring in bioequivalence studies. David, V; Medvedovici, A; Sora, DI; Udrescu, S, 2007)	0.34
" Other important prescribing considerations are that, unlike all first-generation and some second-generation antihistamines, desloratadine is nonsedating at its clinically approved dosage and does not impair psychomotor function."	( Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. DuBuske, L, 2007)	1.99
" Except for maximum observed concentration during a dosing interval (Cmax,ss) of 3-hydroxydesloratadine, on average, there were no statistically significant differences in mean plasma concentrations in any of the main pharmacokinetic parameters of rupatadine, desloratadine, and 3-hydroxydesloratadine when administered in combination with azithromycin or alone."	( Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study. Antonijoan, R; Barbanoj, M; Carbó, ML; Donado, E; Izquierdo, I; Merlos, M; Nadal, T; Peña, J; Solans, A, 2008)	0.57
"Increased dosing of nonsedating antihistamines is recommended by the current European Academy of Allergology and Clinical Immunology/Global Allergy and Asthma European Network/European Dermatology Forum guidelines on patients with acquired cold urticaria (ACU) who do not respond satisfactorily to the standard dose."	( High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. Degener, F; Martus, P; Maurer, M; Siebenhaar, F; Zuberbier, T, 2009)	0.76
" This study supports current guidelines that increased desloratadine dosing might benefit patients with urticaria who do not respond to standard doses."	( High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. Degener, F; Martus, P; Maurer, M; Siebenhaar, F; Zuberbier, T, 2009)	1
" Mean reductions in nasal congestion scores were comparable between the once- and twice-daily dosing regimens of the combination drug."	( Desloratadine and pseudoephedrine combination therapy as a comprehensive treatment for allergic rhinitis and nasal congestion. Anolik, R, 2009)	1.8
"hr/ml (157%), respectively, after dosing with 10 mg loratadine tablets for 10 days."	( Metabolism of loratadine and further characterization of its in vitro metabolites. Alton, KB; Alvarez, N; Chowdhury, SK; Ghosal, A; Gupta, S; Lu, X; Ramanathan, R; Su, AD; Yuan, Y; Zbaida, S, 2009)	0.35
" This method was also suitable for the assay determination of desloratadine in pharmaceutical dosage forms."	( A validated stability-indicating UPLC method for desloratadine and its impurities in pharmaceutical dosage forms. Chakole, D; Malleswara Reddy, A; Mukkanti, K; Rao, DD; Sait, SS; Satyanarayana, NV, 2010)	0.86
" Alternative dosage forms such as liquids or oral disintegrating tablets are available for most agents, allowing ease of administration to most young children and infants; however, limited data are available regarding use in infants for most agents, except desloratadine, cetirizine and montelukast."	( Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. Moeller, ML; Nahata, MC; Phan, H, 2009)	0.53
"Increasing the dosage of levocetirizine and desloratadine up to 4-fold improves chronic urticaria symptoms without compromising safety in approximately three quarters of patients with difficult-to-treat chronic urticaria."	( The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. Church, DS; Church, MK; Dimitrov, V; Kraeva, S; Kralimarkova, T; Lazarova, C; Popov, TA; Popova, D; Staevska, M, 2010)	0.89
" In vivo studies were conducted, in which FVB wild-type and FVB/Mrp2(-/-) mice were dosed with fosinopril and the known MRP2 substrate methotrexate, and tissues collected after 1 h."	( Mrp2 is involved in the efflux and disposition of fosinopril. Bain, LJ; Green, BR, 2013)	0.39
" Because starch is a very common excipient used in solid dosage formulations, the results of this compatibility study should facilitate pharmaceutical development involving secondary amine APIs and starch."	( A compatibility study of a secondary amine active pharmaceutical ingredient with starch: identification of a novel degradant formed between desloratadine and a starch impurity using LC-MS(n) and NMR spectroscopy. Buevich, AV; Li, M; Rustum, AM; Wang, X; Yu, X, 2013)	0.59
"Patients, especially children, are the most difficult to treat in all groups of population mainly because they can not swallow the solid dosage form."	( Optimization and evaluation of desloratadine oral strip: an innovation in paediatric medication. Kaur, M; Singh, H; Verma, H, 2013)	0.68
" Compared to the dexchlorpheniramine plus betamethasone combination, it showed similar clinical action, but with a lower incidence of adverse events and higher dosing convenience."	( Association between desloratadine and prednisolone in the treatment of children with acute symptoms of allergic rhinitis: a double-blind, randomized and controlled clinical trial. Amazonas, RB; Ensina, LF; Miranda, C; Sano, F; Silva, JMD; Solé, D; Wandalsen, GF, )	0.45
" Once the disease is completely controlled, however, maintenance of the same dosage for at least 8 weeks before dose reduction is suggested in order to avoid recurrence of the symptoms."	( The treatment outcomes and dose de-escalation of desloratadine up-dosing in chronic spontaneous urticaria. Chaowattanapanit, S; Choonhakarn, C; Julanon, N, 2018)	0.74
" In cases of failure, treatment was switched to omalizumab at doses of < 300 mg/month with incremental dosage increases as necessary (monthly dose range, 150-600 mg/month)."	( Real-life experience in the treatment of solar urticaria: retrospective cohort study. Enk, CD; Hodak, E; Lapidoth, M; Levi, A; Mazor, S; Snast, I; Uvaidov, V, 2019)	0.51
"A stability-indicating method (SIM) stipulates the testing of the drug product and drug substances under the stressed conditions that will imply a clear notion about the stress conditions that would affect the drug in its finished dosage form."	( Surveillance of Stability Under Different Stress Conditions in Desloratadine and Study of Degradation Kinetics. Pandey, R; Pandey, S; Shukla, SS, 2022)	0.96

Role	Description
H1-receptor antagonist	H1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
anti-allergic agent	A drug used to treat allergic reactions.
cholinergic antagonist	Any drug that binds to but does not activate cholinergic receptors, thereby blocking the actions of acetylcholine or cholinergic agonists.
drug metabolite	null
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
benzocycloheptapyridine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Desloratadine H1-Antihistamine Action	8	7

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	22.0163	0.0447	17.8581	100.0000	AID485294; AID485341
acetylcholinesterase	Homo sapiens (human)	Potency	35.5945	0.0025	41.7960	15,848.9004	AID1347395; AID1347398
chaperonin-containing TCP-1 beta subunit homolog	Homo sapiens (human)	Potency	89.1251	3.9811	27.7649	39.8107	AID504842
TDP1 protein	Homo sapiens (human)	Potency	12.3618	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	2.0248	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	19.6040	0.0002	21.2231	8,912.5098	AID1259243; AID743042; AID743054
thioredoxin glutathione reductase	Schistosoma mansoni	Potency	44.6684	0.1000	22.9075	100.0000	AID485364
caspase 7, apoptosis-related cysteine protease	Homo sapiens (human)	Potency	33.4915	0.0133	26.9810	70.7614	AID1346978
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	11.8832	0.0006	57.9133	22,387.1992	AID1259378
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	35.4289	0.0010	22.6508	76.6163	AID1224838; AID1224839; AID1224893
progesterone receptor	Homo sapiens (human)	Potency	31.6704	0.0004	17.9460	75.1148	AID1346784; AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	16.0794	0.0123	7.9835	43.2770	AID1346984; AID1645841
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	12.8499	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	8.8450	0.0015	30.6073	15,848.9004	AID1224841; AID1259401
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	29.8470	0.3758	27.4851	61.6524	AID743217
pregnane X nuclear receptor	Homo sapiens (human)	Potency	23.8085	0.0054	28.0263	1,258.9301	AID1346982; AID1346985
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	21.8569	0.0002	29.3054	16,493.5996	AID1259248; AID743069; AID743079; AID743080; AID743091
G	Vesicular stomatitis virus	Potency	10.9640	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	10.9640	0.0010	8.3798	61.1304	AID1645840
bromodomain adjacent to zinc finger domain 2B	Homo sapiens (human)	Potency	50.1187	0.7079	36.9043	89.1251	AID504333
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	29.8470	0.0010	24.5048	61.6448	AID743215
caspase-3	Homo sapiens (human)	Potency	33.4915	0.0133	26.9810	70.7614	AID1346978
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	39.8107	0.0355	20.9770	89.1251	AID504332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	33.4915	0.0017	23.8393	78.1014	AID743083
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	26.6032	0.0016	28.0151	77.1139	AID1259385; AID1259395
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a	Homo sapiens (human)	Potency	15.0890	19.7391	45.9784	64.9432	AID1159509
Histone H2A.x	Cricetulus griseus (Chinese hamster)	Potency	61.9315	0.0391	47.5451	146.8240	AID1224845
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	50.1187	0.3548	28.0659	89.1251	AID504847
potassium voltage-gated channel subfamily H member 2 isoform d	Homo sapiens (human)	Potency	12.5893	0.0178	9.6374	44.6684	AID588834
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	10.0151	0.0003	23.4451	159.6830	AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	11.8823	0.0006	27.2152	1,122.0200	AID743202
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	28.6954	0.0056	12.3677	36.1254	AID624032
lamin isoform A-delta10	Homo sapiens (human)	Potency	7.1912	0.8913	12.0676	28.1838	AID1487
Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)	Potency	25.1189	0.3162	12.7657	31.6228	AID881
Interferon beta	Homo sapiens (human)	Potency	10.9640	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	10.9640	0.0123	8.9648	39.8107	AID1645842
Cellular tumor antigen p53	Homo sapiens (human)	Potency	33.4915	0.0023	19.5956	74.0614	AID651631
Histamine H2 receptor	Cavia porcellus (domestic guinea pig)	Potency	25.1189	0.0063	8.2350	39.8107	AID881
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	39.8107	0.0096	10.5250	35.4813	AID1479145
Inositol monophosphatase 1	Rattus norvegicus (Norway rat)	Potency	1.7559	1.0000	10.4756	28.1838	AID1457
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	10.9640	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	10.9640	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
5-hydroxytryptamine receptor 4	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	0.0300	0.0001	1.0076	8.7800	AID625218
5-hydroxytryptamine receptor 4	Cavia porcellus (domestic guinea pig)	Ki	0.0160	0.0000	0.8871	10.0000	AID625218
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	133.0000	0.1100	7.1903	10.0000	AID1473738
Aldo-keto reductase family 1 member B1	Rattus norvegicus (Norway rat)	IC50 (µMol)	1.1160	0.0004	1.8773	10.0000	AID625207
Aldo-keto reductase family 1 member B1	Rattus norvegicus (Norway rat)	Ki	1.1070	0.0032	2.2887	9.3160	AID625207
Muscarinic acetylcholine receptor M2	Homo sapiens (human)	IC50 (µMol)	0.1070	0.0000	1.2326	7.7930	AID625152
Muscarinic acetylcholine receptor M2	Homo sapiens (human)	Ki	0.0380	0.0000	0.6902	10.0000	AID625152
Muscarinic acetylcholine receptor M4	Homo sapiens (human)	IC50 (µMol)	0.3390	0.0000	1.1546	7.5858	AID625154
Muscarinic acetylcholine receptor M4	Homo sapiens (human)	Ki	0.0470	0.0000	0.7951	9.1201	AID625154
ATP-dependent translocase ABCB1	Homo sapiens (human)	IC50 (µMol)	43.0000	0.0002	2.3185	10.0000	AID679465
Muscarinic acetylcholine receptor M5	Homo sapiens (human)	IC50 (µMol)	0.2920	0.0001	0.9917	8.0000	AID625155
Muscarinic acetylcholine receptor M5	Homo sapiens (human)	Ki	0.2100	0.0000	0.7292	6.9183	AID625155
Muscarinic acetylcholine receptor M1	Homo sapiens (human)	IC50 (µMol)	0.2670	0.0000	1.4039	10.0000	AID625151
Muscarinic acetylcholine receptor M1	Homo sapiens (human)	Ki	0.0640	0.0000	0.5972	9.1201	AID625151
Alpha-2B adrenergic receptor	Homo sapiens (human)	IC50 (µMol)	2.1460	0.0000	1.2380	8.1590	AID625202
Alpha-2B adrenergic receptor	Homo sapiens (human)	Ki	0.9800	0.0002	0.7257	10.0000	AID625202
Muscarinic acetylcholine receptor M3	Homo sapiens (human)	IC50 (µMol)	0.4460	0.0001	1.0104	9.9280	AID625153
Muscarinic acetylcholine receptor M3	Homo sapiens (human)	Ki	0.0950	0.0000	0.5405	7.7600	AID625153
Sodium-dependent noradrenaline transporter	Homo sapiens (human)	IC50 (µMol)	1.1160	0.0008	1.5416	20.0000	AID625207
Sodium-dependent noradrenaline transporter	Homo sapiens (human)	Ki	1.1070	0.0003	1.4656	10.0000	AID625207
Histamine H2 receptor	Homo sapiens (human)	IC50 (µMol)	1.0990	0.0220	2.2987	10.0000	AID625270
Histamine H2 receptor	Homo sapiens (human)	Ki	1.0800	0.0006	2.1973	10.0000	AID625270
5-hydroxytryptamine receptor 2A	Homo sapiens (human)	IC50 (µMol)	0.0330	0.0001	0.8801	8.8500	AID625192
5-hydroxytryptamine receptor 2A	Homo sapiens (human)	Ki	0.0094	0.0000	0.3855	10.0000	AID625192
5-hydroxytryptamine receptor 2C	Homo sapiens (human)	IC50 (µMol)	0.0300	0.0001	1.0302	9.0000	AID625218
5-hydroxytryptamine receptor 2C	Homo sapiens (human)	Ki	0.0160	0.0001	0.9549	10.0000	AID625218
Sodium-dependent serotonin transporter	Homo sapiens (human)	IC50 (µMol)	0.2300	0.0001	0.8645	8.7096	AID625222
Sodium-dependent serotonin transporter	Homo sapiens (human)	Ki	0.1220	0.0000	0.7048	8.1930	AID625222
Histamine H1 receptor	Homo sapiens (human)	IC50 (µMol)	0.0059	0.0000	0.4436	5.1768	AID1611227; AID625269
Histamine H1 receptor	Homo sapiens (human)	Ki	0.0012	0.0000	0.5110	10.0000	AID1569605; AID238825; AID625269
D(3) dopamine receptor	Homo sapiens (human)	IC50 (µMol)	1.9060	0.0001	1.0178	8.7960	AID625254
D(3) dopamine receptor	Homo sapiens (human)	Ki	0.6470	0.0000	0.6020	10.0000	AID625254
5-hydroxytryptamine receptor 2B	Homo sapiens (human)	IC50 (µMol)	0.0430	0.0001	1.1873	8.9125	AID625217
5-hydroxytryptamine receptor 2B	Homo sapiens (human)	Ki	0.0280	0.0003	0.7693	10.0000	AID625217
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)	IC50 (µMol)	65.0000	0.0005	0.4716	10.0000	AID72658
Protein farnesyltransferase subunit beta	Homo sapiens (human)	IC50 (µMol)	65.0000	0.0005	0.2177	2.5000	AID72658
5-hydroxytryptamine receptor 6	Homo sapiens (human)	IC50 (µMol)	2.1710	0.0017	0.8381	5.4200	AID625221
5-hydroxytryptamine receptor 6	Homo sapiens (human)	Ki	1.0080	0.0002	0.5229	10.0000	AID625221
Sodium-dependent dopamine transporter	Homo sapiens (human)	IC50 (µMol)	3.8790	0.0007	1.8419	46.0000	AID625256
Sodium-dependent dopamine transporter	Homo sapiens (human)	Ki	3.0820	0.0002	1.1115	8.0280	AID625256
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
Sodium-dependent neutral amino acid transporter B(0)AT2	Homo sapiens (human)	IC50 (µMol)	172.0000	4.0000	4.0000	4.0000	AID1169507
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Histamine H1 receptor	Homo sapiens (human)	Kd	0.0240	0.0001	0.4021	5.4000	AID1668948
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
lipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
phospholipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
apoptotic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell population proliferation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell migration	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
prostate gland development	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
regulation of epithelial cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of chemokine production	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of keratinocyte differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell cycle	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of growth	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
hepoxilin biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
endocannabinoid signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cannabinoid biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxin A4 biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid oxidation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxygenase pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
nervous system development	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
regulation of heart contraction	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
response to virus	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
regulation of smooth muscle contraction	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
signal transduction	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
cell surface receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
regulation of locomotion	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G2/M transition of mitotic cell cycle	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic metabolic process	ATP-dependent translocase ABCB1	Homo sapiens (human)
response to xenobiotic stimulus	ATP-dependent translocase ABCB1	Homo sapiens (human)
phospholipid translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
terpenoid transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of response to osmotic stress	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
transepithelial transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
stem cell proliferation	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
export across plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
positive regulation of anion channel activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of chloride transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
gastric acid secretion	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
dopamine transport	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
transmission of nerve impulse	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
regulation of phosphatidylinositol dephosphorylation	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
positive regulation of monoatomic ion transport	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
signal transduction	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
neuromuscular synaptic transmission	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
nervous system development	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
regulation of locomotion	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
saliva secretion	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
cognition	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
regulation of postsynaptic membrane potential	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
regulation of glial cell proliferation	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
positive regulation of intracellular protein transport	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmission	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
MAPK cascade	Alpha-2B adrenergic receptor	Homo sapiens (human)
angiogenesis	Alpha-2B adrenergic receptor	Homo sapiens (human)
regulation of vascular associated smooth muscle contraction	Alpha-2B adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-2B adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-2B adrenergic receptor	Homo sapiens (human)
female pregnancy	Alpha-2B adrenergic receptor	Homo sapiens (human)
negative regulation of norepinephrine secretion	Alpha-2B adrenergic receptor	Homo sapiens (human)
platelet activation	Alpha-2B adrenergic receptor	Homo sapiens (human)
activation of protein kinase B activity	Alpha-2B adrenergic receptor	Homo sapiens (human)
negative regulation of epinephrine secretion	Alpha-2B adrenergic receptor	Homo sapiens (human)
receptor transactivation	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of neuron differentiation	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of blood pressure	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of uterine smooth muscle contraction	Alpha-2B adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Alpha-2B adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-2B adrenergic receptor	Homo sapiens (human)
calcium-mediated signaling	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
smooth muscle contraction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
signal transduction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
synaptic transmission, cholinergic	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
nervous system development	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
positive regulation of insulin secretion	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
protein modification process	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
positive regulation of smooth muscle contraction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
saliva secretion	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
ligand-gated ion channel signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
regulation of smooth muscle contraction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
monoamine transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
chemical synaptic transmission	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
response to xenobiotic stimulus	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
response to pain	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine uptake	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neuron cellular homeostasis	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
amino acid transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
sodium ion transmembrane transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
gastric acid secretion	Histamine H2 receptor	Homo sapiens (human)
immune response	Histamine H2 receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Histamine H2 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Histamine H2 receptor	Homo sapiens (human)
chemical synaptic transmission	Histamine H2 receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Histamine H2 receptor	Homo sapiens (human)
temperature homeostasis	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of cytokine production involved in immune response	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
glycolytic process	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
intracellular calcium ion homeostasis	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
activation of phospholipase C activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
memory	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of cell population proliferation	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
response to xenobiotic stimulus	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
regulation of dopamine secretion	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
artery smooth muscle contraction	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
urinary bladder smooth muscle contraction	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of heat generation	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
negative regulation of potassium ion transport	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of neuron apoptotic process	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein localization to cytoskeleton	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of fat cell differentiation	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of glycolytic process	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of vasoconstriction	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
symbiont entry into host cell	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
sensitization	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
behavioral response to cocaine	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of inflammatory response	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
release of sequestered calcium ion into cytosol	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergic	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of execution phase of apoptosis	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of platelet aggregation	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of DNA biosynthetic process	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
behavioral fear response	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
intracellular calcium ion homeostasis	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
locomotory behavior	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
feeding behavior	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
cGMP-mediated signaling	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
regulation of nervous system process	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
regulation of appetite	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
regulation of corticotropin-releasing hormone secretion	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
positive regulation of fat cell differentiation	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
positive regulation of calcium-mediated signaling	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
release of sequestered calcium ion into cytosol	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
monoamine transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to hypoxia	Sodium-dependent serotonin transporter	Homo sapiens (human)
neurotransmitter transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to nutrient	Sodium-dependent serotonin transporter	Homo sapiens (human)
memory	Sodium-dependent serotonin transporter	Homo sapiens (human)
circadian rhythm	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to xenobiotic stimulus	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to toxic substance	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of gene expression	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of serotonin secretion	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferation	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergic	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to estradiol	Sodium-dependent serotonin transporter	Homo sapiens (human)
social behavior	Sodium-dependent serotonin transporter	Homo sapiens (human)
vasoconstriction	Sodium-dependent serotonin transporter	Homo sapiens (human)
sperm ejaculation	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of neuron differentiation	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of cell cycle	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of organ growth	Sodium-dependent serotonin transporter	Homo sapiens (human)
behavioral response to cocaine	Sodium-dependent serotonin transporter	Homo sapiens (human)
enteric nervous system development	Sodium-dependent serotonin transporter	Homo sapiens (human)
brain morphogenesis	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin uptake	Sodium-dependent serotonin transporter	Homo sapiens (human)
membrane depolarization	Sodium-dependent serotonin transporter	Homo sapiens (human)
platelet aggregation	Sodium-dependent serotonin transporter	Homo sapiens (human)
cellular response to retinoic acid	Sodium-dependent serotonin transporter	Homo sapiens (human)
cellular response to cGMP	Sodium-dependent serotonin transporter	Homo sapiens (human)
regulation of thalamus size	Sodium-dependent serotonin transporter	Homo sapiens (human)
conditioned place preference	Sodium-dependent serotonin transporter	Homo sapiens (human)
sodium ion transmembrane transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
amino acid transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
inflammatory response	Histamine H1 receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Histamine H1 receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Histamine H1 receptor	Homo sapiens (human)
memory	Histamine H1 receptor	Homo sapiens (human)
visual learning	Histamine H1 receptor	Homo sapiens (human)
regulation of vascular permeability	Histamine H1 receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Histamine H1 receptor	Homo sapiens (human)
regulation of synaptic plasticity	Histamine H1 receptor	Homo sapiens (human)
cellular response to histamine	Histamine H1 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Histamine H1 receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Histamine H1 receptor	Homo sapiens (human)
chemical synaptic transmission	Histamine H1 receptor	Homo sapiens (human)
response to ethanol	D(3) dopamine receptor	Homo sapiens (human)
synaptic transmission, dopaminergic	D(3) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor internalization	D(3) dopamine receptor	Homo sapiens (human)
intracellular calcium ion homeostasis	D(3) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
learning or memory	D(3) dopamine receptor	Homo sapiens (human)
learning	D(3) dopamine receptor	Homo sapiens (human)
locomotory behavior	D(3) dopamine receptor	Homo sapiens (human)
visual learning	D(3) dopamine receptor	Homo sapiens (human)
response to xenobiotic stimulus	D(3) dopamine receptor	Homo sapiens (human)
regulation of dopamine secretion	D(3) dopamine receptor	Homo sapiens (human)
positive regulation of cytokinesis	D(3) dopamine receptor	Homo sapiens (human)
circadian regulation of gene expression	D(3) dopamine receptor	Homo sapiens (human)
response to histamine	D(3) dopamine receptor	Homo sapiens (human)
social behavior	D(3) dopamine receptor	Homo sapiens (human)
response to cocaine	D(3) dopamine receptor	Homo sapiens (human)
dopamine metabolic process	D(3) dopamine receptor	Homo sapiens (human)
response to morphine	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of blood pressure	D(3) dopamine receptor	Homo sapiens (human)
positive regulation of mitotic nuclear division	D(3) dopamine receptor	Homo sapiens (human)
acid secretion	D(3) dopamine receptor	Homo sapiens (human)
behavioral response to cocaine	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of oligodendrocyte differentiation	D(3) dopamine receptor	Homo sapiens (human)
arachidonic acid secretion	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of protein secretion	D(3) dopamine receptor	Homo sapiens (human)
musculoskeletal movement, spinal reflex action	D(3) dopamine receptor	Homo sapiens (human)
regulation of dopamine uptake involved in synaptic transmission	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	D(3) dopamine receptor	Homo sapiens (human)
prepulse inhibition	D(3) dopamine receptor	Homo sapiens (human)
positive regulation of dopamine receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of adenylate cyclase activity	D(3) dopamine receptor	Homo sapiens (human)

Process	via Protein(s)	Taxonomy
iron ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
calcium ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
protein binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 13S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 8(S)-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 15-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 9S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
arrestin family protein binding	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
protein binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
efflux transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP hydrolysis activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ubiquitin protein ligase binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylcholine floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylethanolamine flippase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylinositol phospholipase C activity	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
protein binding	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
phosphatidylinositol phospholipase C activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
protein binding	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
alpha2-adrenergic receptor activity	Alpha-2B adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-2B adrenergic receptor	Homo sapiens (human)
epinephrine binding	Alpha-2B adrenergic receptor	Homo sapiens (human)
phosphatidylinositol phospholipase C activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
protein binding	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
signaling receptor activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
acetylcholine binding	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
actin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
dopamine:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
protein binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
alpha-tubulin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
metal ion binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
beta-tubulin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
histamine receptor activity	Histamine H2 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Histamine H2 receptor	Homo sapiens (human)
neurotransmitter receptor activity	Histamine H2 receptor	Homo sapiens (human)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
virus receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein tyrosine kinase activator activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
identical protein binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein-containing complex binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
identical protein binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
integrin binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoatomic cation channel activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin:sodium:chloride symporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
protein binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
antiporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
syntaxin-1 binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
cocaine binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
sodium ion binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
identical protein binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
nitric-oxide synthase binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
actin filament binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
histamine receptor activity	Histamine H1 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Histamine H1 receptor	Homo sapiens (human)
neurotransmitter receptor activity	Histamine H1 receptor	Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/Go	D(3) dopamine receptor	Homo sapiens (human)
protein binding	D(3) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor activity	D(3) dopamine receptor	Homo sapiens (human)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G-protein alpha-subunit binding	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
GTPase activator activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
protein farnesyltransferase activity	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
protein farnesyltransferase activity	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
protein geranylgeranyltransferase activity	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
Rab geranylgeranyltransferase activity	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
protein binding	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
microtubule binding	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
receptor tyrosine kinase binding	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
alpha-tubulin binding	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
molecular adaptor activity	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
CAAX-protein geranylgeranyltransferase activity	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
protein farnesyltransferase activity	Protein farnesyltransferase subunit beta	Homo sapiens (human)
protein farnesyltransferase activity	Protein farnesyltransferase subunit beta	Homo sapiens (human)
protein binding	Protein farnesyltransferase subunit beta	Homo sapiens (human)
zinc ion binding	Protein farnesyltransferase subunit beta	Homo sapiens (human)
histamine receptor activity	5-hydroxytryptamine receptor 6	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 6	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 6	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 6	Homo sapiens (human)
protease binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
signaling receptor binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine:sodium symporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
protein binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
amine binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
protein-containing complex binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
metal ion binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
protein phosphatase 2A binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
heterocyclic compound binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
norepinephrine:sodium symporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
neutral L-amino acid:sodium symporter activity	Sodium-dependent neutral amino acid transporter B(0)AT2	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent neutral amino acid transporter B(0)AT2	Homo sapiens (human)
protein binding	Sodium-dependent neutral amino acid transporter B(0)AT2	Homo sapiens (human)
amino acid transmembrane transporter activity	Sodium-dependent neutral amino acid transporter B(0)AT2	Homo sapiens (human)
branched-chain amino acid:sodium symporter activity	Sodium-dependent neutral amino acid transporter B(0)AT2	Homo sapiens (human)
proline:sodium symporter activity	Sodium-dependent neutral amino acid transporter B(0)AT2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytosol	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytoskeleton	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
plasma membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
adherens junction	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
focal adhesion	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
extracellular exosome	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
clathrin-coated endocytic vesicle membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
asymmetric synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
symmetric synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
presynaptic membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
neuronal cell body	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
axon terminus	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
glutamatergic synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
cholinergic synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
cytoplasm	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
cell surface	ATP-dependent translocase ABCB1	Homo sapiens (human)
membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
extracellular exosome	ATP-dependent translocase ABCB1	Homo sapiens (human)
external side of apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
presynaptic membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
axon terminus	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
postsynaptic density membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
glutamatergic synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
cholinergic synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
cytosol	Alpha-2B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2B adrenergic receptor	Homo sapiens (human)
cell surface	Alpha-2B adrenergic receptor	Homo sapiens (human)
intracellular membrane-bounded organelle	Alpha-2B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2B adrenergic receptor	Homo sapiens (human)
endoplasmic reticulum membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
basal plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
basolateral plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
plasma membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
cell surface	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neuronal cell body membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
axon	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
plasma membrane	Histamine H2 receptor	Homo sapiens (human)
synapse	Histamine H2 receptor	Homo sapiens (human)
plasma membrane	Histamine H2 receptor	Homo sapiens (human)
dendrite	Histamine H2 receptor	Homo sapiens (human)
neurofilament	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
caveola	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
axon	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
cytoplasmic vesicle	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
presynaptic membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
neuronal cell body	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
dendritic shaft	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
cell body fiber	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
glutamatergic synapse	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
plasma membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
focal adhesion	Sodium-dependent serotonin transporter	Homo sapiens (human)
endosome membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
endomembrane system	Sodium-dependent serotonin transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
membrane raft	Sodium-dependent serotonin transporter	Homo sapiens (human)
synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
postsynaptic membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonergic synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
neuron projection	Sodium-dependent serotonin transporter	Homo sapiens (human)
cytosol	Histamine H1 receptor	Homo sapiens (human)
plasma membrane	Histamine H1 receptor	Homo sapiens (human)
synapse	Histamine H1 receptor	Homo sapiens (human)
dendrite	Histamine H1 receptor	Homo sapiens (human)
plasma membrane	Histamine H1 receptor	Homo sapiens (human)
plasma membrane	D(3) dopamine receptor	Homo sapiens (human)
synapse	D(3) dopamine receptor	Homo sapiens (human)
plasma membrane	D(3) dopamine receptor	Homo sapiens (human)
nucleoplasm	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
cytoplasm	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
cytosol	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
plasma membrane	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
CAAX-protein geranylgeranyltransferase complex	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
microtubule associated complex	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
protein farnesyltransferase complex	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
cytoplasm	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
cytosol	Protein farnesyltransferase subunit beta	Homo sapiens (human)
microtubule associated complex	Protein farnesyltransferase subunit beta	Homo sapiens (human)
protein farnesyltransferase complex	Protein farnesyltransferase subunit beta	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 6	Homo sapiens (human)
cilium	5-hydroxytryptamine receptor 6	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 6	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 6	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 6	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
cytoplasm	Sodium-dependent dopamine transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
cell surface	Sodium-dependent dopamine transporter	Homo sapiens (human)
membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
axon	Sodium-dependent dopamine transporter	Homo sapiens (human)
neuron projection	Sodium-dependent dopamine transporter	Homo sapiens (human)
neuronal cell body	Sodium-dependent dopamine transporter	Homo sapiens (human)
axon terminus	Sodium-dependent dopamine transporter	Homo sapiens (human)
membrane raft	Sodium-dependent dopamine transporter	Homo sapiens (human)
postsynaptic membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopaminergic synapse	Sodium-dependent dopamine transporter	Homo sapiens (human)
flotillin complex	Sodium-dependent dopamine transporter	Homo sapiens (human)
axon	Sodium-dependent dopamine transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
neuronal cell body membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
plasma membrane	Sodium-dependent neutral amino acid transporter B(0)AT2	Homo sapiens (human)
membrane	Sodium-dependent neutral amino acid transporter B(0)AT2	Homo sapiens (human)
plasma membrane	Sodium-dependent neutral amino acid transporter B(0)AT2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID684453	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by crystal violet staining	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	Synthesis and biological evaluation of cyanoguanidine derivatives of loratadine.
AID658410	Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 144 hrs by crystal violet staining method	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	Design and synthesis of thiourea derivatives containing a benzo[5,6]cyclohepta[1,2-b]pyridine moiety as potential antitumor and anti-inflammatory agents.
AID238825	Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells	2004	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22	Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.
AID1057863	Cytotoxicity against mouse dividing ScN2a-cl3 cells assessed as cell viability after 5 days by calcein-AM staining-based fluorescence assay	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells.
AID1668951	Apparent permeability in RRCK cells	2020	Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13	Late-Stage Lead Diversification Coupled with Quantitative Nuclear Magnetic Resonance Spectroscopy to Identify New Structure-Activity Relationship Vectors at Nanomole-Scale Synthesis: Application to Loratadine, a Human Histamine H
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID547621	Cytotoxicity against BESM cells after 88 hrs by HTS assay	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID1569612	Antagonist activity at H1R in human HeLa cells assessed as inhibition of histamine-induced intracellular calcium mobilization at 10 times Ki incubated for 18 to 20 hrs prior to Fluo-4NW dye addition for 1 hr followed by compound washout and subsequent sti	2019	Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14	Route to Prolonged Residence Time at the Histamine H
AID1611248	Toxicity in Sprague-Dawley rat	2019	Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24	Design, synthesis and biological evaluation of novel desloratadine derivatives with anti-inflammatory and H
AID1611249	Toxicity in ICR mouse	2019	Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24	Design, synthesis and biological evaluation of novel desloratadine derivatives with anti-inflammatory and H
AID701311	Ratio of brain to plasma ratio in mdr1a deficient mouse to brain to plasma ratio in mdr1a expressing mouse at 5 mg/kg, iv	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Structural modifications that alter the P-glycoprotein efflux properties of compounds.
AID755981	Toxicity in mouse assessed as change in mental state at 1 mg/kg measured for 7 days	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Design, synthesis and biological activity evaluation of desloratadine analogues as H1 receptor antagonists.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID755994	Toxicity in mouse assessed as effect on pentobarbital sodium-induced hypnotic effect measured as loss of righting reflex latency at 1 mg/kg pretreated for 30 mins prior to pentobarbital sodium-challenge	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Design, synthesis and biological activity evaluation of desloratadine analogues as H1 receptor antagonists.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1611227	Antagonist activity at histamine H1 receptor (unknown origin)	2019	Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24	Design, synthesis and biological evaluation of novel desloratadine derivatives with anti-inflammatory and H
AID458627	Antagonist activity at histamine H1 receptor in Dunkin-Hartley guinea pig ileum assessed as inhibition of histamine-induced contractions at 10 umol/L	2010	Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4	Stereoselective synthesis of desloratadine derivatives as antagonist of histamine.
AID462891	Inhibition of protein farnesyltransferase by continuous fluorescence assay	2010	Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6	Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1764402	Unbound brain-to-plasma concentration ratio in P-gp knock out Sprague-Dawley rat	2021	Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5	Development of an
AID755966	Toxicity in guinea pig ileum assessed as effect on acetylcholine-induced smooth muscle spasm at 1 ug/mL after 3 mins (Rvb = 1.31 +/- 3.66%)	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Design, synthesis and biological activity evaluation of desloratadine analogues as H1 receptor antagonists.
AID92393	In vitro antagonist activity, determined by 50% inhibition of PAF-induced platelet aggregation of human platelet rich plasma when challenged with PAF	1998	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 8, Issue:24	Dual antagonists of platelet activating factor and histamine. 3. Synthesis, biological activity and conformational implications of substituted N-acyl-bis-arylcycloheptapiperazines.
AID1611228	Anti-inflammatory activity in DNFB-induced mouse ear edema model assessed as swelling at 5 mg/kg (Rvb = 17.4 +/- 3.6 mg/kg)	2019	Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24	Design, synthesis and biological evaluation of novel desloratadine derivatives with anti-inflammatory and H
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID755979	Toxicity in mouse assessed as change in body activity at 1 mg/kg measured for 7 days	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Design, synthesis and biological activity evaluation of desloratadine analogues as H1 receptor antagonists.
AID458628	Antagonist activity at histamine H1 receptor in Dunkin-Hartley guinea pig ileum assessed as inhibition of histamine-induced contractions at 30 umol/L	2010	Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4	Stereoselective synthesis of desloratadine derivatives as antagonist of histamine.
AID1764401	Ratio of drug concentration in brain to plasma of P-gp knock out Sprague-Dawley rat	2021	Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5	Development of an
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1668948	Binding affinity to human H1 histamine receptor expressed in CHO cells after 1 hr by calcium 5 dye-based FLIPR assay	2020	Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13	Late-Stage Lead Diversification Coupled with Quantitative Nuclear Magnetic Resonance Spectroscopy to Identify New Structure-Activity Relationship Vectors at Nanomole-Scale Synthesis: Application to Loratadine, a Human Histamine H
AID755992	Antagonist activity at histamine H1 receptor in guinea pig ileum assessed as inhibition of histamine-induced smooth muscle contraction at 0.2 mg/mL after 3 mins (Rvb = 3.37 +/- 1.05 g)	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Design, synthesis and biological activity evaluation of desloratadine analogues as H1 receptor antagonists.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1668952	Octanol/water partition coefficient, log D of compound at pH 7.4 by shake-flask method	2020	Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13	Late-Stage Lead Diversification Coupled with Quantitative Nuclear Magnetic Resonance Spectroscopy to Identify New Structure-Activity Relationship Vectors at Nanomole-Scale Synthesis: Application to Loratadine, a Human Histamine H
AID1222793	Dissociation constant, pKa of the compound	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Which metabolites circulate?
AID684452	Cytotoxicity against human MCF7 cells after 72 hrs by crystal violet staining	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	Synthesis and biological evaluation of cyanoguanidine derivatives of loratadine.
AID1057864	Ratio of LC50 for dividing mouse ScN2a-cl3 cells to EC50 for inhibition of RML prion protein	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells.
AID1569609	Displacement of [3H]levocetirizine from N-terminal HA-tagged H1R (unknown origin) expressed in HEK293T cells assessed as residence time by microbeta scintillation counting method	2019	Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14	Route to Prolonged Residence Time at the Histamine H
AID547804	Selectivity window, ratio of EC50 for BESM cells to EC50 for Trypanosoma cruzi amastigotes infected in BESM cells	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID1569605	Displacement of [3H]mepyramine from N-terminal HA-tagged H1R (unknown origin) expressed in HEK293T cells measured after 4 hrs by microbeta scintillation counting method	2019	Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14	Route to Prolonged Residence Time at the Histamine H
AID1169507	Inhibition of eGFP-tagged human B0AT2 expressed in HEK293 cells measured within 10 mins by [3H]proline uptake assay	2014	Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22	Loratadine and analogues: discovery and preliminary structure-activity relationship of inhibitors of the amino acid transporter B(0)AT2.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1057862	Inhibition of RML prion protein infected in mouse dividing ScN2a-cl3 cells expressing full length mouse PrP assessed as reduction of PrPsc level after 5 days by ELISA	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1764398	Substrate activity at P-gp (unknown origin) assessed as net efflux ratio	2021	Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5	Development of an
AID1611229	Anti-inflammatory activity in DNFB-induced mouse ear edema model assessed as inhibition in ear swelling at 5 mg/kg relative to control	2019	Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24	Design, synthesis and biological evaluation of novel desloratadine derivatives with anti-inflammatory and H
AID755976	Toxicity in mouse assessed as effect on pentobarbital sodium-induced hypnotic effect measured as recovery of righting reflex at 1 mg/kg pretreated for 30 mins prior to pentobarbital sodium-challenge	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Design, synthesis and biological activity evaluation of desloratadine analogues as H1 receptor antagonists.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID755973	Toxicity in guinea pig ileum assessed as effect on acetylcholine-induced smooth muscle contraction at 1 ug/mL after 3 mins (Rvb = 5.17 +/- 0.36 g)	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Design, synthesis and biological activity evaluation of desloratadine analogues as H1 receptor antagonists.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1569608	Displacement of [3H]levocetirizine from N-terminal HA-tagged H1R (unknown origin) expressed in HEK293T cells assessed as dissociation rate constant by microbeta scintillation counting method	2019	Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14	Route to Prolonged Residence Time at the Histamine H
AID1668950	Intrinsic clearance in human hepatocytes at 0.2 nmol assessed per million cells up to 240 mins in presence of NADPH by LC-MS/MS analysis	2020	Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13	Late-Stage Lead Diversification Coupled with Quantitative Nuclear Magnetic Resonance Spectroscopy to Identify New Structure-Activity Relationship Vectors at Nanomole-Scale Synthesis: Application to Loratadine, a Human Histamine H
AID1668949	Intrinsic clearance in human liver microsomes at 10 uM incubated up to 60 mins in presence of NADPH by LC-MS/MS analysis	2020	Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13	Late-Stage Lead Diversification Coupled with Quantitative Nuclear Magnetic Resonance Spectroscopy to Identify New Structure-Activity Relationship Vectors at Nanomole-Scale Synthesis: Application to Loratadine, a Human Histamine H
AID1569610	Kinetic rate index, ratio of compound effect for displacement of [3H]levocetirizine from N-terminal HA-tagged H1R (unknown origin) expressed in HEK293T cells at Ki measured after 6 hrs to compound effect for displacement of [3H]levocetirizine from N-termi	2019	Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14	Route to Prolonged Residence Time at the Histamine H
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID684454	Cytotoxicity against human HT-29 cells after 72 hrs by crystal violet staining	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	Synthesis and biological evaluation of cyanoguanidine derivatives of loratadine.
AID241255	Inhibition of 5-lipoxygenase activity in human whole blood assay; not tested	2004	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22	Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.
AID72658	FPT inhibitory activity was determined by the ability to inhibit the transfer of [3H]farnesyl from farnesyl pyrophosphate to H-ras-CLVS	2002	Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4	Synthesis of 5,6-dihydro-11H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidine-N-cyanoguanidine derivatives as inhibitors of ras farnesyl protein transferase.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID658408	Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 144 hrs by crystal violet staining method	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	Design and synthesis of thiourea derivatives containing a benzo[5,6]cyclohepta[1,2-b]pyridine moiety as potential antitumor and anti-inflammatory agents.
AID679465	TP_TRANSPORTER: inhibition of Daunorubicin efflux (Daunorubicin: ? uM) in G185 cells	2001	Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 29, Issue:8	Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein.
AID1569607	Displacement of [3H]mepyramine from N-terminal HA-tagged H1R (unknown origin) expressed in HEK293T cells assessed as residence time by microbeta scintillation counting method	2019	Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14	Route to Prolonged Residence Time at the Histamine H
AID658409	Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 144 hrs by crystal violet staining method	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	Design and synthesis of thiourea derivatives containing a benzo[5,6]cyclohepta[1,2-b]pyridine moiety as potential antitumor and anti-inflammatory agents.
AID1569606	Displacement of [3H]mepyramine from N-terminal HA-tagged H1R (unknown origin) expressed in HEK293T cells measured after 80 mins by microbeta scintillation counting method	2019	Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14	Route to Prolonged Residence Time at the Histamine H
AID547622	Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID701301	Efflux ratio of permeability in MDCK cells expressing human MDR1	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Structural modifications that alter the P-glycoprotein efflux properties of compounds.
AID1611230	Immunosuppressive activity in BALB/C mouse assessed as inhibition in TNFalpha production by TNFalpha level at 5 mg/kg by ELISA	2019	Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24	Design, synthesis and biological evaluation of novel desloratadine derivatives with anti-inflammatory and H
AID755991	Antagonist activity at histamine H1 receptor in guinea pig ileum assessed as inhibition of histamine-induced smooth muscle spasm at 0.2 mg/mL after 3 mins (Rvb = 1.27 +/- 5.65%)	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Design, synthesis and biological activity evaluation of desloratadine analogues as H1 receptor antagonists.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1764399	Unbound plasma concentration in P-gp knock out Sprague-Dawley rat at 5 mg/ml/kg, po measured upto 4 hrs by LC-MS analysis	2021	Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5	Development of an
AID755990	Antiasthamatic activity in histamine-induced guinea pig asthma model assessed as prolongation of asthmogenic latent period at 1 mg/kg, ig pretreated for 60 mins prior to histamine-challenge (Rvb = 127.10 +/- 40.46 seconds)	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Design, synthesis and biological activity evaluation of desloratadine analogues as H1 receptor antagonists.
AID458626	Antagonist activity at histamine H1 receptor in Dunkin-Hartley guinea pig ileum assessed as inhibition of histamine-induced contractions at 3 umol/L	2010	Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4	Stereoselective synthesis of desloratadine derivatives as antagonist of histamine.
AID1764400	Unbound brain concentration in P-gp knock out Sprague-Dawley rat at 5 mg/ml/kg, po measured upto 4 hrs by LC-MS analysis	2021	Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5	Development of an
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1224864	HCS microscopy assay (F508del-CFTR)	2016	PloS one, , Volume: 11, Issue:10	Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1346037	Human H1 receptor (Histamine receptors)	2004	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22	Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (0.23)	18.7374
1990's	9 (2.11)	18.2507
2000's	227 (53.29)	29.6817
2010's	142 (33.33)	24.3611
2020's	47 (11.03)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	146 (31.40%)	5.53%
Reviews	49 (10.54%)	6.00%
Case Studies	32 (6.88%)	4.05%
Observational	0 (0.00%)	0.25%
Other	238 (51.18%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (67)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Single-Dose, Two-Way Crossover Relative Bioavailability Study of Desloratadine 5 mg Tablet in Healthy Subjects Under Fed Conditions [NCT01314352]	Phase 1	28 participants (Actual)	Interventional	2005-12-31	Completed
Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter/Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis Who Meet the Criteria for Persistent Allergic Rhinitis (PER) [NCT00405964]	Phase 3	716 participants (Actual)	Interventional	2006-09-30	Completed
A Study of the Efficacy, Safety, and Quality of Life (QOL) in Patients With Chronic Idiopathic Urticaria Dosed With AERIUS Tablets (Desloratadine 5 mg, 10 mg, or 20 mg Once Daily) [NCT00536380]	Phase 4	314 participants (Actual)	Interventional	2007-09-30	Completed
Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter/Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis Who Meet the Criteria for Intermittent Allergic Rhinitis (IAR) [NCT00406783]	Phase 3	547 participants (Actual)	Interventional	2006-08-31	Completed
Preference Evaluation of Clarinex Tablets vs. Allegra Tablets in Subjects With Symptomatic Seasonal Allergic Rhinitis [NCT00794248]	Phase 4	122 participants (Actual)	Interventional	2002-11-30	Completed
Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Desloratadine Tablet Among Filipino Patients [NCT00724698]		3,011 participants (Actual)	Observational	2005-10-31	Completed
Double-blind, Randomized, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Desloratadine 5 mg for the Treatment of Seasonal Allergic Rhinitis [NCT01108783]	Phase 3	720 participants (Actual)	Interventional	2003-04-30	Completed
Randomized, Open-Label, 2-Way Crossover, Bioequivalence Study of Desloratadine and Pseudoephedrine 5 mg/240 mg Extended-Release Tablet and Clarinex-D® 24-Hour (Reference) Following a 5 mg/240 mg Dose in Healthy Subjects Under Fasting Conditions [NCT01373138]	Phase 1	34 participants (Actual)	Interventional	2006-04-30	Completed
A Randomized, Single-Dose, Two-Way Crossover Relative Bioavailability Study of Desloratadine 5 mg Tablet in Healthy Subjects Under Fasting Conditions [NCT01314339]	Phase 1	28 participants (Actual)	Interventional	2005-12-31	Completed
A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (CIU) [NCT00751166]	Phase 4	149 participants (Actual)	Interventional	2004-03-01	Terminated(stopped due to Study could not be re-supplied with study medication in a timely manner.)
Evaluation of the Efficacy and Safety of Desloratadine Syrup in Childhood Atopic Dermatitis [NCT00817076]	Phase 3	40 participants (Actual)	Interventional	2003-03-31	Completed
A Single-Center, Pediatric, Comparative Taste Test of Desloratadine and Cetirizine Antihistamine Syrup Medications [NCT00794378]	Phase 3	202 participants (Actual)	Interventional	2004-11-30	Completed
The Effects of Desloratadine and Levocetirizine on Nasal Obstruction in Subjects With Induced Allergic Rhinitis in the VCC Assessed Clinically and With Nasal Rhinomanometry and Nasal Flowmetry [NCT00789152]	Phase 3	81 participants (Actual)	Interventional	2003-12-01	Completed
A Placebo Controlled Study of the Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. in the Treatment of Subjects With Symptomatic Seasonal Allergic Rhinitis (SAR) [NCT00783146]	Phase 4	728 participants (Actual)	Interventional	2004-08-01	Completed
An Open-Label Study of the Effects of Desloratadine Treatment on the Quality of Life of Patients With Chronic Urticaria [NCT00795158]	Phase 3	282 participants (Actual)	Interventional	2002-11-30	Completed
Preference Evaluation of Clarinex Tablets vs. Zyrtec Tablets in Subjects With Symptomatic Allergic Rhinitis [NCT00794846]	Phase 4	124 participants (Actual)	Interventional	2002-12-31	Completed
Preference Evaluation of Clarinex Tablets vs. Allegra Tablets in Subjects With Symptomatic Seasonal Allergic Rhinitis [NCT00794768]	Phase 4	118 participants (Actual)	Interventional	2002-11-30	Completed
Efficacy and Safety of Desloratadine 10 mg Daily vs. Placebo in Subjects With Allergic Airway Disease During the Pollen Season [NCT00779636]	Phase 4	506 participants (Actual)	Interventional	2003-07-01	Completed
Multiple-Dose Safety and Tolerance Study of Desloratadine in Atopic Pediatric Subjects and Pediatric Subjects With Chronic Idiopathic Urticaria, Ages >=2 to <12 Years, Who Are Poor Metabolizers of Desloratadine [NCT00757562]	Phase 3	97 participants (Actual)	Interventional	2002-11-01	Completed
Validation of a Rhinitis Control Tool : the Rhinitis Control Scoring System (RCSS) [NCT00967967]		50 participants (Anticipated)	Interventional	2009-03-31	Suspended(stopped due to Awaiting results from sub analysis to decide if study continuesé)
"A Pilot, Multicenter, Double-blind Randomized Study for Comparison of Aerius® Continuous Treatment Versus Aerius® PRN Regimen on Chronic Idiopathic Urticaria Patient Quality of Life" [NCT00783354]	Phase 4	129 participants (Actual)	Interventional	2003-04-01	Completed
A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis [NCT05232825]	Phase 3	236 participants (Actual)	Interventional	2022-05-03	Active, not recruiting
Multicenter, Randomized, Parallel, Double-blind, Comparative Study of the Superiority of the FDC of Desloratadine 0.5 mg/mL and Prednisolone 4 mg/mL Versus Desloratadine 0.5 mg/mL in the Treat. of Persistent Allergic Rhinitis in Children [NCT05214911]	Phase 3	248 participants (Anticipated)	Interventional	2024-03-30	Not yet recruiting
Evaluation of the Efficacy and Safety of Desloratadine Syrup in Children Suffering From Seasonal Allergic Rhinitis With or Without Intermittent Asthma [NCT00805324]	Phase 3	54 participants (Actual)	Interventional	2003-05-31	Completed
Randomized, Double-blind, Placebo/Active-controlled, Multi-center Clinical Trial to Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg After 14-day Oral Administration in Patients With Seasonal Allergic Rhinitis [NCT01400828]	Phase 3	239 participants (Actual)	Interventional	2011-06-30	Completed
Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Desloratadine Syrup Among Filipino Pediatric Patients [NCT00761527]		2,980 participants (Actual)	Observational	2008-03-31	Completed
A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (CIU) [NCT00751218]	Phase 4	174 participants (Actual)	Interventional	2004-05-06	Completed
A Double-blind, Placebo-controlled, Crossover, Single-center Study to Evaluate the Anti-allergic and Anti-inflammatory Effects of Multiple Doses of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms [NCT00311844]	Phase 4	41 participants (Actual)	Interventional	2005-03-01	Completed
Pilot Efficacy and Safety Field Trial of Desloratadine Administered Concomitantly With Oxybutynin, in Subjects With Seasonal Allergic Rhinitis and Post-Nasal Drip [NCT00816972]	Phase 2	540 participants (Actual)	Interventional	2005-04-30	Completed
A Multi-center, Open-label, Non-comparative Study of the Relief of Nasal Symptoms and Tolerability in Subjects With Seasonal Allergic Rhinitis (SAR) Treated With Aerius. [NCT00805584]	Phase 4	311 participants (Actual)	Interventional	2003-05-31	Completed
A Comparative Study on Clinical Efficacy and Safety of Levocetirizine 5 mg Oral Capsules Once Daily in the Morning vs. Desloratadine 5 mg Oral Capsules Once Daily in the Morning in Patients Suffering From Chronic Idiopathic Urticaria (CIU) [NCT00264303]	Phase 4	886 participants (Actual)	Interventional	2005-12-31	Completed
Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria [NCT01940393]	Phase 4	150 participants (Actual)	Interventional	2013-08-31	Completed
Airway Responses to Montelukast and Desloratadine. [NCT00424580]		12 participants	Interventional	2007-01-31	Completed
The Effect of Antihistamines on Methacholine Challenge Testing in Asthma Patients [NCT01985789]	Phase 4	12 participants (Actual)	Interventional	2013-11-30	Completed
Peanut Allergy Oral Immunotherapy Desensitization [NCT01601522]	Phase 2	43 participants (Actual)	Interventional	2012-02-29	Completed
An Exploratory Phase III, Randomised, Double-blind, Therapeutic Single Dose-related Effect, Parallel Group Study to Assess and Compare the Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU) [NCT00598611]	Phase 3	29 participants (Actual)	Interventional	2007-09-30	Completed
Aprepitant vs. Desloratadine in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Related Pruritus: A Prospective, Randomized Control, Double-blinded, Phase II Clinical Trial [NCT02646020]	Phase 2	138 participants (Actual)	Interventional	2015-12-31	Completed
A Single-Center, Pediatric, Comparative Taste Test of Desloratadine and Cetirizine Antihistamine Syrup Medications [NCT00794794]	Phase 3	204 participants (Actual)	Interventional	2004-11-30	Completed
A Placebo Controlled Study of the Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. in the Treatment of Subjects With Symptomatic Seasonal Allergic Rhinitis (SAR) [NCT00783211]	Phase 4	722 participants (Actual)	Interventional	2004-08-01	Completed
An Exploratory Phase IV, Randomised, Double-Blind, Placebo Controlled Crossover Study to Compare the Effects of 5 mg vs. 20 mg Desloratadine on the Development of Experimentally Induced Urticaria Lesions [NCT00600847]	Phase 4	33 participants (Actual)	Interventional	2006-11-30	Completed
Influence of H1-antihistamines on the Dermal Blood Flow Response After a Histamine Skin Prick as Well as After the Topical Application of Cinnamaldehyde and Capsaicin [NCT04399525]		12 participants (Actual)	Interventional	2019-10-28	Completed
An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria [NCT00795522]	Phase 4	51 participants (Actual)	Interventional	2003-07-31	Completed
A Double-blind,Double Dummy, Randomized, Multicenter Parallel-group Study on Efficacy of Desloratadine and Prednisolone Association Compared to Dexchlorpheniramine and Betamethasone Association in Adults With Moderate - Severe Persistent Allergic Rhinitis [NCT01720485]	Phase 3	234 participants (Anticipated)	Interventional	2013-10-31	Not yet recruiting
National Clinical Trial,Phase III, Multicenter, Randomized, Prospective, Double-blind, Parallel, Placebo-controlled, to Evaluate the Efficacy, Safety and Superiority of Decongex Gripe in the Treatment of Symptoms Associated With Common Cold [NCT02904304]	Phase 3	150 participants (Anticipated)	Interventional	2020-12-31	Suspended(stopped due to the viability of the study is being analyzed)
A Double-blind, Randomized, Multicenter Parallel-group Study on Efficacy of Desloratadine and Prednisolone Association Compared to Dexchlorpheniramine and Betamethasone Association in Children (2-12 Years) With Moderate - Severe Persistent Allergic Rhinit [NCT01529229]	Phase 3	210 participants (Actual)	Interventional	2013-11-30	Completed
A Double-blind, Randomized, Multicenter Parallel-group Study on Efficacy of Desloratadine and Prednisolone Association Compared to Dexchlorpheniramine and Betamethasone Association in Children (2-12 Years) With Acute Cutaneous Rash [NCT01529242]	Phase 3	17 participants (Actual)	Interventional	2014-02-28	Terminated(stopped due to By sponsor decision due to difficulty of recruitment)
A Randomised, Double-blind, Placebo-controlled Trial Assessing the Efficacy of SLITone in House Dust Mite Allergic Patients [NCT00633919]	Phase 2/Phase 3	124 participants (Actual)	Interventional	2006-07-31	Completed
A Double-blind, Double-dummy, Parallel-group, Placebo-controlled, Randomized Study to Assess the Duration of the Suppressive Effects of Desloratadine on the Cutaneous Allergen-induced Wheal and Flare (1) Response After Discontinuation [NCT00359138]	Phase 4	36 participants (Actual)	Interventional	2006-02-28	Completed
Influence of Antipruritics on the Dermal Blood Flow Response After a Histamine Skin Prick as Well as After the Topical Application of Cinnamaldehyde and Capsaicin [NCT04399148]		13 participants (Actual)	Interventional	2019-06-11	Completed
Potential Off-label Use of Desloratadine to Mitigate Inflammation Caused by PPE-induced Heat Stress [NCT05446480]		12 participants (Anticipated)	Interventional	2022-07-31	Recruiting
Randomized, Single Dose, 2-Way Crossover, Relative Bioavailability Study of Desloratadine Orally Disintegrating Tablet Fed Conditions [NCT01506037]	Phase 1	36 participants (Actual)	Interventional	2006-01-31	Completed
Randomized, Single Dose, 2-Way Crossover, Relative Bioavailability Study of Desloratadine Orally Disintegrating Tablet Fasting Conditions [NCT01506050]	Phase 1	35 participants (Actual)	Interventional	2006-01-31	Completed
Randomized, Open-Label, 2-Way Crossover, Bioequivalence Study of Desloratadine and Pseudoephedrine 5 mg/240 mg Extended-Release Tablet and Clarinex-D® 24-Hour (Reference) Following a 5 mg/240 mg Dose in Healthy Subjects Under Fed Conditions [NCT01506791]	Phase 1	44 participants (Actual)	Interventional	2006-04-30	Completed
Multi-center, Double Blind, Dose Escalating Study to Compare the Effects of 5 mg, 10mg and 20mg of Desloratadine in Patients With Acquired Cold Urticaria (ACU) [NCT01444196]	Phase 4	30 participants (Actual)	Interventional	2009-08-31	Completed
A Phase III, Multi-Center, Randomized, Parallel-Group, Placebo-Controlled and Double- Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Perennial Allergic Rhinitis [NCT01918033]	Phase 3	608 participants (Actual)	Interventional	2013-08-20	Completed
A Phase III Multicentre, Parallel-group, Randomized, Placebo-controlled, Double-blind Clinical Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Chronic Urticaria. [NCT01916967]	Phase 3	239 participants (Actual)	Interventional	2013-08-27	Completed
Non-Interventional Study of the Safe Use of Aerius in Pediatric Patients With Allergic Rhinitis or Chronic Idiopathic Urticaria. [NCT00723736]		100 participants (Actual)	Observational	2007-12-31	Completed
A Multi-Centre, Double-Blind, Randomised Comparison Of The Effects Of Desloratadine (Aerius®) And Placebo In The Relief Of Nasal Symptom Scores In Subjects With Seasonal Allergic Rhinitis (Sar) To Cypress Pollen [NCT00867191]	Phase 4	233 participants (Actual)	Interventional	2002-02-01	Completed
Preference Evaluation of Clarinex Tablets vs. Zyrtec Tablets in Subjects With Symptomatic Allergic Rhinitis [NCT00794495]	Phase 4	122 participants (Actual)	Interventional	2002-12-31	Completed
A Phase III, Multicenter, Open-Label Long-Term Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Eczema/Dermatitis and Dermal Pruritus. [NCT01916980]	Phase 3	94 participants (Actual)	Interventional	2013-08-27	Completed
A Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications [NCT00779116]	Phase 4	217 participants (Actual)	Interventional	2005-09-30	Completed
Observational Study Evaluating the Safety and Efficacy of Desloratadine Syrup for Perennial Allergic Rhinitis in Indonesian Pediatric Patients [NCT00704769]		591 participants (Actual)	Observational	2005-05-31	Completed
Preference Evaluation of Clarinex Tablets vs. Zyrtec Tablets in Subjects With Symptomatic Allergic Rhinitis [NCT00794599]	Phase 4	118 participants (Actual)	Interventional	2002-12-31	Completed
Preference Evaluation of Clarinex Tablets vs. Allegra Tablets in Subjects With Symptomatic Seasonal Allergic Rhinitis [NCT00783133]	Phase 4	131 participants (Actual)	Interventional	2002-11-01	Completed
A Phase III, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Seasonal Allergic Rhinitis [NCT02320396]	Phase 3	449 participants (Actual)	Interventional	2015-01-09	Completed
A Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications [NCT00780403]	Phase 4	220 participants (Actual)	Interventional	2005-08-31	Completed
In Vivo Anti-inflammatory Effect of H1 Antihistamines in Allergic Rhinitis [NCT02507635]	Phase 4	115 participants (Actual)	Interventional	2009-02-28	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00264303 (6) [back to overview]	Mean Pruritus Severity Score Over the Four Weeks of Treatment
NCT00264303 (6) [back to overview]	Mean Chronic Idiopathic Urticaria (CIU) Composite Score Over the First Week of Treatment
NCT00264303 (6) [back to overview]	Mean Chronic Idiopathic Urticaria (CIU) Composite Score Over the Four Weeks of Treatment
NCT00264303 (6) [back to overview]	Mean Pruritus Severity Score Over the First Week of Treatment
NCT00264303 (6) [back to overview]	Mean Score for Pruritus Duration Over the First Week of Treatment
NCT00264303 (6) [back to overview]	Mean Score for Pruritus Duration Over the Four Weeks of Treatment
NCT00359138 (1) [back to overview]	Duration of Suppressive Effect of Desloratadine After Discontinuation of a 1-week Treatment
NCT00405964 (3) [back to overview]	Change From Baseline in Participant's AM/PM PRIOR Total 5 Symptom Score (T5SS) Over Days 1 to 29 of Treatment
NCT00405964 (3) [back to overview]	Change From Baseline in the Total Rhinoconjunctivitis Quality of Life Questionnaire-Standarized Version (RQLQ-S) After 29 Days of Treatment
NCT00405964 (3) [back to overview]	Change From Baseline in Participant's AM/PM PRIOR T5SS Over Days 1 to 85 of Treatment
NCT00406783 (4) [back to overview]	Change From Baseline in the Rhinoconjunctivitis Quality of Life Questionnaire-Standardized Version (RQLQ-S) at the Final Visit
NCT00406783 (4) [back to overview]	Rhinoconjunctivitis Quality of Life Questionnaire-Standardized Version (RQLQ-S: BASELINE
NCT00406783 (4) [back to overview]	The Change From Baseline in the 12-hour AM/PM-PRIOR (Reflective) Total 5 Symptom Score (T5SS) From Subject Daily Diaries Averaged Over Treatment Days 1 to 15
NCT00406783 (4) [back to overview]	Total 5 Symptom Score (T5SS) - Average AM/PM PRIOR (Reflective) 12 Hours Diary: BASELINE
NCT00536380 (1) [back to overview]	Change in the Urticaria Activity Score (UAS) From Baseline to the Final Week for Desloratadine 5 mg Versus Desloratadine 20 mg
NCT00633919 (5) [back to overview]	Average Daily Asthma Medication Score During a 2-months Evaluation Period in Autumn 2007
NCT00633919 (5) [back to overview]	Average Daily Asthma Medication Score During a 2-months Evaluation Period in Autumn 2008
NCT00633919 (5) [back to overview]	Global Evaluation of Efficacy by Investigator at the End of the Evaluation Period in Autumn 2008
NCT00633919 (5) [back to overview]	Global Evaluation of Efficacy by Subject and Investigator at the End of the Evaluation Period in Autumn 2007
NCT00633919 (5) [back to overview]	Global Evaluation of Efficacy by Subject at the End of The Evaluation Period in 2008
NCT00704769 (2) [back to overview]	General Clinical Response of Desloratadine Syrup Based on the Physician's Judgments
NCT00704769 (2) [back to overview]	Adverse Events
NCT00723736 (1) [back to overview]	Proportion of Patients With Adverse Events
NCT00724698 (1) [back to overview]	Adverse Events
NCT00761527 (4) [back to overview]	Investigator Assessment of Clinical Efficacy
NCT00761527 (4) [back to overview]	Number of Adverse Events Reported By Category After 14 Days of Treatment
NCT00761527 (4) [back to overview]	Participant Global Tolerability Assessment
NCT00761527 (4) [back to overview]	Safety of Desloratadine Syrup Reported by Number of Participants Experiencing Adverse Events After 14 Days of Treatment
NCT00779116 (1) [back to overview]	Number of Subjects Who Preferred Desloratadine RediTab or Zyrtec Chewable Tablet.
NCT00780403 (1) [back to overview]	Number of Subjects Who Preferred Desloratadine RediTab or Zyrtec Chewable Tablet.
NCT01916967 (11) [back to overview]	Change From Baseline in the Rash Score Reported in Participant Diaries at Day 3, Week 1 and Week 2
NCT01916967 (11) [back to overview]	Change From Baseline in the Rash Score Assessed by Investigator at Day 3, Week 1 and Week 2
NCT01916967 (11) [back to overview]	Change From Baseline in the Sum Score of Pruritus/Itch and Rash Assessed by Investigator at Day 3 and Week 1
NCT01916967 (11) [back to overview]	Number of Participants With a Moderate or Remarkable Improvement in the Global Improvement Rate of Both Pruritus/Itch and Rash (Erythema and Wheal) Assessed by the Investigator at Day 3, Week 1 and Week 2
NCT01916967 (11) [back to overview]	Change From Baseline in the Sum Score of Pruritus/Itch and Rash Assessed by Investigator at Week 2
NCT01916967 (11) [back to overview]	Number of Participants Who Discontinued Study Drug Due to an AE
NCT01916967 (11) [back to overview]	Number of Participants Who Experienced at Least One Adverse Event (AE)
NCT01916967 (11) [back to overview]	Change From Baseline in Pruritus/Itch on a Visual Analog Scale (VAS) Reported by Participants at Day 3, Week 1 and Week 2
NCT01916967 (11) [back to overview]	Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score Reported by Participants at Week 1 and Week 2
NCT01916967 (11) [back to overview]	Change From Baseline in the Pruritus/Itch Score Assessed by Investigator at Day 3, Week 1 and Week 2
NCT01916967 (11) [back to overview]	Change From Baseline in the Pruritus/Itch Score Reported in Participant Diaries at Day 3, Week 1 and Week 2
NCT01916980 (6) [back to overview]	Percentage of Participants Who Experienced at Least One Adverse Event (AE)
NCT01916980 (6) [back to overview]	Percentage of Participants Who Discontinued Study Drug Due to an AE
NCT01916980 (6) [back to overview]	Change From Baseline in Pruritus/Itch Score (Sum of Daytime and Nighttime Scores) Assessed by the Investigator at Week 2
NCT01916980 (6) [back to overview]	Change From Baseline in Pruritus/Itch Score (Sum of Daytime and Nighttime Scores) Assessed by the Investigator at Day 3, Week 1, Week 4, Week 6, Week 8 and Week 12
NCT01916980 (6) [back to overview]	Change From Baseline in the Pruritus/Itch Visual Analog Scale (VAS) Score Recorded by Participants at Day 3, Week 1, Week 2, Week 4, Week 6, Week 8 and Week 12
NCT01916980 (6) [back to overview]	Percentage of Participants With Moderate or Remarkable Improvement in the Global Improvement Rate of Pruritus/Itch Assessed by the Investigator at Day 3, Week 1, Week 2, Week 4, Week 6, Week 8 and Week 12
NCT01918033 (11) [back to overview]	Change From Baseline in Nasal Finding Score Assessed by the Investigator
NCT01918033 (11) [back to overview]	Number of Participants With Moderate-to-Remarkable Improvement in Global Improvement Assessed by the Investigator
NCT01918033 (11) [back to overview]	Change From Baseline in Total Nasal Symptom Score (TNSS) Assessed by the Investigator at Day 3 and Week 1
NCT01918033 (11) [back to overview]	Change From Baseline in Total Nasal Symptom Score (TNSS) Assessed by the Investigator at Week 2
NCT01918033 (11) [back to overview]	Number of Participants Discontinuing Study Drug Due to an AE
NCT01918033 (11) [back to overview]	Change From Baseline in Eye Symptom Score Assessed by the Investigator
NCT01918033 (11) [back to overview]	Change From Baseline in Eye Symptom Score Reported in Participant Diaries
NCT01918033 (11) [back to overview]	Change From Baseline in Score on Interference With Daily Activities Assessed by the Investigator
NCT01918033 (11) [back to overview]	Change From Baseline in Nasal Symptom Sub-Scores Reported in Participant Diaries
NCT01918033 (11) [back to overview]	Change From Baseline in Nasal Symptom Sub-Scores Assessed by the Investigator
NCT01918033 (11) [back to overview]	Number of Participants Experiencing an Adverse Event (AE)
NCT02320396 (13) [back to overview]	Number of Participants Who Discontinue Study Drug Due to an AE
NCT02320396 (13) [back to overview]	Number of Participants Who Experience at Least One Adverse Event (AE)
NCT02320396 (13) [back to overview]	"Percentage of Participants With Impression Assessments of Better or Much Better as Assessed by the Investigator at Week 2"
NCT02320396 (13) [back to overview]	"Percentage of Participants With Impression Assessments of Better or Much Better as Assessed Participants at Week 2"
NCT02320396 (13) [back to overview]	Change From Baseline in Total Nasal Symptom Score (TNSS) During 2 Weeks of Therapy
NCT02320396 (13) [back to overview]	Change From Baseline in Eye Symptoms (Pruritus, Watering Eyes and the Worse One of Either Pruritus or Watering Eyes) During 2 Weeks of Therapy
NCT02320396 (13) [back to overview]	Change From Baseline in Interference With Daily Activities Score at Week 1, Week 2, and During 2 Weeks of Therapy
NCT02320396 (13) [back to overview]	Change From Baseline in TNSS for Week 1 and Week 2 of Double-blind Treatment
NCT02320396 (13) [back to overview]	Change From Baseline to Week 1 in Each Nasal Symptom Sub-Score (Sneezing, Rhinorrhea, Nasal Congestion and Nasal Itching)
NCT02320396 (13) [back to overview]	Change From Baseline to Week 1 in Eye Symptoms (Pruritus, Watering Eyes and the Worse One of Either Pruritus or Watering Eyes)
NCT02320396 (13) [back to overview]	Change From Baseline to Week 2 in Each Nasal Symptom Sub-Score (Sneezing, Rhinorrhea, Nasal Congestion and Nasal Itching)
NCT02320396 (13) [back to overview]	Change From Baseline to Week 2 in Eye Symptoms (Pruritus, Watering Eyes and the Worse One of Either Pruritus or Watering Eyes)
NCT02320396 (13) [back to overview]	Change From Baseline in Each Nasal Symptom Sub-Score (Sneezing, Rhinorrhea, Nasal Congestion and Nasal Itching) During 2 Weeks of Therapy

Mean Pruritus Severity Score Over the Four Weeks of Treatment

Pruritus severity is evaluated on an ordinal 4-point scale from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe/intense). Mean pruritus severity score is averaged over the four weeks of treatment. (NCT00264303)
Timeframe: over the four weeks of treatment

Intervention	Units on a scale (Least Squares Mean)
Levocetirizine 5 mg	0.86
Desloratadine 5 mg	0.99

Intervention	Days (Mean)
Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule	5
Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule	4
Desloratadine Placebo Tablet + Levocetirizine Placebo Capsule	NA

Intervention	units on a scale (Least Squares Mean)
	Baseline	Days 1-29
5-mg Desloratadine Tablet	9.63	-3.76
Placebo Tablet	9.55	-2.87

Intervention	units on a scale (Least Squares Mean)
	Baseline	Day 29
5-mg Desloratadine Tablet	3.30	-1.35
Placebo Tablet	3.15	-0.95

Intervention	units on a scale (Least Squares Mean)
	Baseline	Days 1-85
5-mg Desloratadine Tablet	9.63	-4.50
Placebo Tablet	9.55	-3.61

Intervention	Units on a scale (Least Squares Mean)
	Change from Baseline in UAS	Baseline UAS (mean +/- standard deviation)
10-mg Desloratadine	-1.1	2.9
20-mg Desloratadine	-1.0	2.8
5-mg Desloratadine	-1.0	2.9

Intervention	Participants (Number)
	Investigator evaluation: Improved	Investigator evaluation: Not improved	Investigator evaluation: Missing data
Active	30	7	0
Placebo	24	17	0

Intervention	Participants (Number)
	Subject evalution: Improved	Subject evaluation: Not improved	Investigator evaluation: Improved	Investigator evaluation: Not improved
Active	30	17	33	14
Placebo	33	14	30	17

Intervention	Participants (Number)
	Subject evaluation: Improved	Subject evaluation: Not improved	Subject evaluation: Missing data
Active	28	8	1
Placebo	28	13	0

Intervention	participants (Number)
	Gastrointestinal Disorders	General Disorders & Administration Site Conditions	Infections and Infestations	Respiratory, Thoracic, and Mediastinal Disorders	Skin and Subcutaneous Tissue Disorders
Aerius® Syrup	20	4	21	6	4

Intervention	Participants (Number)
	Improvement	No Improvement	Worsened
Desloratadine (Aerius) Syrup	2913	39	0

Intervention	Adverse Events (Number)
	Total Number of AEs	Number of Mild AEs	Number of Moderate AEs	Number of Severe AEs	Number of Treatment-related AEs	Number of Mild Treatment-related AEs	Number of Moderate Treatment-related AEs	Number of Severe Treatment-related AEs	Number of SAEs	Number of Treatment-related SAEs
Desloratadine (Aerius) Syrup	26	21	4	1	20	19	0	1	1	0

Intervention	Participants (Number)
	Excellent	Very Good	Good	Fair	Poor
Desloratadine (Aerius) Syrup	1278	1339	307	15	8

Intervention	Participants (Number)
	Number of Participants with AEs	Number of Participants with Mild AEs	Number of Participants with Moderate AEs	Number of Participants with Severe AEs	Number of Participants with Treatment-related AEs	Number of Participants with AEs - Temporary d/c	Number of Participants with AEs - Permanent d/c	Number of Participants with AEs - Withdrawal	Number of Participants with SAEs	Number of Participants with Treatment-related SAEs	Number of Participants Who Died Due to AEs
Desloratadine (Aerius) Syrup	24	21	2	1	20	1	2	2	1	0	0

Intervention	Score on a Scale (Least Squares Mean)
	Change from Baseline at Day 3	Change from Baseline at Week 1	Change from Baseline at Week 2
Desloratadine 10 mg	-2.31	-2.43	-2.45
Desloratadine 5 mg	-2.21	-2.15	-2.51
Placebo	-0.77	-1.17	-1.70

Intervention	Participants (Number)
	Day 3	Week 1	Week 2
Desloratadine 10 mg	55	58	53
Desloratadine 5 mg	54	54	59
Placebo	15	32	38

Intervention	Percentage of Participants (Number)
Desloratadine: Eczema/Dermatitis	53.8
Desloratadine: Dermal Pruritus	48.3

Intervention	Score on a Scale (Least Squares Mean)
Desloratadine: Eczema/Dermatitis	-1.63
Desloratadine: Dermal Pruritus	-2.17

Intervention	Score on a Scale (Least Squares Mean)
	Change from Baseline at Day 3 (n=65, 29)	Change from Baseline at Week 1 (n=65, 29)	Change from Baseline at Week 4 (n=63, 28)	Change from Baseline at Week 6 (n=62, 26)	Change from Baseline at Week 8 (n=61, 25)	Change from Baseline at Week 12 (n=58, 25)
Desloratadine: Dermal Pruritus	-1.59	-2.07	-2.39	-2.48	-3.15	-3.47
Desloratadine: Eczema/Dermatitis	-0.83	-1.29	-1.88	-2.33	-2.18	-2.51

Intervention	Score on a Scale (Least Squares Mean)
	Change from Baseline at Day 3 (n=65, 29)	Change from Baseline at Week 1 (n=65, 29)	Change from Baseline at Week 2 (n=63, 29)	Change from Baseline at Week 4 (n=63, 28)	Change from Baseline at Week 6 (n=62, 26)	Change from Baseline at Week 8 (n=61, 25)	Change from Baseline at Week 12 (n=58, 25)
Desloratadine: Dermal Pruritus	-21.90	-24.72	-28.45	-27.74	-30.71	-32.44	-38.74
Desloratadine: Eczema/Dermatitis	-10.03	-12.17	-18.95	-22.36	-27.26	-29.87	-33.02

Intervention	Score on a Scale (Least Squares Mean)
	Swelling of INCM: Change from BL at Day 3	Swelling of INCM: Change from BL at Week 1	Swelling of INCM: Change from BL at Week 2	Coloring of INCM: Change from BL at Day 3	Coloring of INCM: Change from BL at Week 1	Coloring of INCM: Change from BL at Week 2	NDP: Change from BL at Day 3	NDP: Change from BL at Week 1	NDP: Change from BL at Week 2
Desloratadine 10 mg	-0.17	-0.31	-0.34	-0.26	-0.38	-0.48	-0.24	-0.36	-0.38
Desloratadine 5 mg	-0.23	-0.35	-0.38	-0.27	-0.35	-0.48	-0.23	-0.33	-0.41
Placebo	-0.13	-0.34	-0.32	-0.26	-0.40	-0.45	-0.18	-0.41	-0.44

desloratadine

Description

Cross-References

Synonyms (166)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (4)

Drug Classes (1)

Pathways (1)

Protein Targets (68)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (439)

Molecular Functions (136)

Ceullar Components (83)

Bioassays (125)

Research

Studies (426)

Market Indicators

Research Demand Index: 122.39

Study Types

Clinical Trials (67)

Trial Overview

Trial Outcomes

Mean Pruritus Severity Score Over the Four Weeks of Treatment

Mean Chronic Idiopathic Urticaria (CIU) Composite Score Over the First Week of Treatment

Mean Chronic Idiopathic Urticaria (CIU) Composite Score Over the Four Weeks of Treatment

Mean Pruritus Severity Score Over the First Week of Treatment

Mean Score for Pruritus Duration Over the First Week of Treatment

Mean Score for Pruritus Duration Over the Four Weeks of Treatment

Duration of Suppressive Effect of Desloratadine After Discontinuation of a 1-week Treatment

Change From Baseline in Participant's AM/PM PRIOR Total 5 Symptom Score (T5SS) Over Days 1 to 29 of Treatment

Change From Baseline in the Total Rhinoconjunctivitis Quality of Life Questionnaire-Standarized Version (RQLQ-S) After 29 Days of Treatment

Change From Baseline in Participant's AM/PM PRIOR T5SS Over Days 1 to 85 of Treatment

Change From Baseline in the Rhinoconjunctivitis Quality of Life Questionnaire-Standardized Version (RQLQ-S) at the Final Visit

Rhinoconjunctivitis Quality of Life Questionnaire-Standardized Version (RQLQ-S: BASELINE

The Change From Baseline in the 12-hour AM/PM-PRIOR (Reflective) Total 5 Symptom Score (T5SS) From Subject Daily Diaries Averaged Over Treatment Days 1 to 15

Total 5 Symptom Score (T5SS) - Average AM/PM PRIOR (Reflective) 12 Hours Diary: BASELINE

Change in the Urticaria Activity Score (UAS) From Baseline to the Final Week for Desloratadine 5 mg Versus Desloratadine 20 mg

Average Daily Asthma Medication Score During a 2-months Evaluation Period in Autumn 2007

Average Daily Asthma Medication Score During a 2-months Evaluation Period in Autumn 2008

Global Evaluation of Efficacy by Investigator at the End of the Evaluation Period in Autumn 2008

Global Evaluation of Efficacy by Subject and Investigator at the End of the Evaluation Period in Autumn 2007

Global Evaluation of Efficacy by Subject at the End of The Evaluation Period in 2008

General Clinical Response of Desloratadine Syrup Based on the Physician's Judgments

Adverse Events

Proportion of Patients With Adverse Events

Adverse Events

Investigator Assessment of Clinical Efficacy

Number of Adverse Events Reported By Category After 14 Days of Treatment

Participant Global Tolerability Assessment

Safety of Desloratadine Syrup Reported by Number of Participants Experiencing Adverse Events After 14 Days of Treatment

Number of Subjects Who Preferred Desloratadine RediTab or Zyrtec Chewable Tablet.

Number of Subjects Who Preferred Desloratadine RediTab or Zyrtec Chewable Tablet.

Change From Baseline in the Rash Score Reported in Participant Diaries at Day 3, Week 1 and Week 2

Change From Baseline in the Rash Score Assessed by Investigator at Day 3, Week 1 and Week 2

Change From Baseline in the Sum Score of Pruritus/Itch and Rash Assessed by Investigator at Day 3 and Week 1

Number of Participants With a Moderate or Remarkable Improvement in the Global Improvement Rate of Both Pruritus/Itch and Rash (Erythema and Wheal) Assessed by the Investigator at Day 3, Week 1 and Week 2

Change From Baseline in the Sum Score of Pruritus/Itch and Rash Assessed by Investigator at Week 2

Number of Participants Who Discontinued Study Drug Due to an AE

Number of Participants Who Experienced at Least One Adverse Event (AE)

Change From Baseline in Pruritus/Itch on a Visual Analog Scale (VAS) Reported by Participants at Day 3, Week 1 and Week 2

Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score Reported by Participants at Week 1 and Week 2

Change From Baseline in the Pruritus/Itch Score Assessed by Investigator at Day 3, Week 1 and Week 2

Change From Baseline in the Pruritus/Itch Score Reported in Participant Diaries at Day 3, Week 1 and Week 2

Percentage of Participants Who Experienced at Least One Adverse Event (AE)

Percentage of Participants Who Discontinued Study Drug Due to an AE

Change From Baseline in Pruritus/Itch Score (Sum of Daytime and Nighttime Scores) Assessed by the Investigator at Week 2

Change From Baseline in Pruritus/Itch Score (Sum of Daytime and Nighttime Scores) Assessed by the Investigator at Day 3, Week 1, Week 4, Week 6, Week 8 and Week 12

Change From Baseline in the Pruritus/Itch Visual Analog Scale (VAS) Score Recorded by Participants at Day 3, Week 1, Week 2, Week 4, Week 6, Week 8 and Week 12

Percentage of Participants With Moderate or Remarkable Improvement in the Global Improvement Rate of Pruritus/Itch Assessed by the Investigator at Day 3, Week 1, Week 2, Week 4, Week 6, Week 8 and Week 12

Intervention	Participants (Number)
	Day 3 (n=199, 201, 200)	Week 1 (n=200, 203, 201)	Week 2 (n=200, 203, 201)
Desloratadine 10 mg	61	83	93
Desloratadine 5 mg	67	72	96
Placebo	53	91	106

Intervention	Score on a Scale (Least Squares Mean)
	Change from Baseline (BL) at Day 3	Change from BL at Week 1
Desloratadine 10 mg	-1.11	-1.39
Desloratadine 5 mg	-1.12	-1.39
Placebo	-0.63	-1.48

Intervention	Score on a Scale (Least Squares Mean)
	Change from BL at Day 3	Change from BL at Week 1	Change from BL at Week 2
Desloratadine 10 mg	-0.24	-0.35	-0.44
Desloratadine 5 mg	-0.17	-0.28	-0.38
Placebo	-0.13	-0.26	-0.37

Intervention	Score on a Scale (Least Squares Mean)
	Sneezing: Change from BL at Day 3	Sneezing: Change from BL at Week 1	Sneezing: Change from BL at Week 2	Rhinorrhea: Change from BL at Day 3	Rhinorrhea: Change from BL at Week 1	Rhinorrhea: Change from BL at Week 2	Nasal Congestion: Change from BL at Day 3	Nasal Congestion: Change from BL at Week 1	Nasal Congestion: Change from BL at Week 2	Nasal Itching: Change from BL at Day 3	Nasal Itching: Change from BL at Week 1	Nasal Itching: Change from BL at Week 2
Desloratadine 10 mg	-0.32	-0.40	-0.45	-0.29	-0.36	-0.38	-0.17	-0.24	-0.26	-0.35	-0.42	-0.47
Desloratadine 5 mg	-0.27	-0.38	-0.43	-0.20	-0.29	-0.33	-0.18	-0.23	-0.23	-0.29	-0.40	-0.52
Placebo	-0.23	-0.30	-0.33	-0.17	-0.34	-0.45	-0.18	-0.25	-0.32	-0.22	-0.39	-0.44

Intervention	percentage of participants (Number)
	Much better	Better	Better + Much better Total	Less than better Total
Desloratadine	2.3	26.1	28.4	71.6
Placebo	3.1	17.9	21.0	79.0

Intervention	units on a scale (Least Squares Mean)
	Eye Pruritus	Watering Eyes	Worse of Pruritus or Watering Eyes
Desloratadine	-0.44	-0.21	-0.44
Placebo	-0.19	-0.07	-0.19

Intervention	units on a scale (Least Squares Mean)
	Week 1	Week 2	2 Week Average
Desloratadine	-0.23	-0.34	-0.28
Placebo	-0.07	-0.14	-0.10

Intervention	units on a scale (Least Squares Mean)
	Sneezing	Rhinorrhea	Nasal Congestion	Nasal Itching
Desloratadine	-0.39	-0.34	-0.02	-0.45
Placebo	-0.14	-0.13	0.07	-0.18